

(19) **DANMARK**

(10) **DK/EP 3214094 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **C 07 K 14/405 (2006.01)** **A 61 K 38/00 (2006.01)** **A 61 K 38/16 (2006.01)**
A 61 K 41/00 (2020.01) **A 61 N 5/06 (2006.01)** **C 12 N 13/00 (2006.01)**
C 12 Q 1/02 (2006.01) **G 01 N 33/487 (2006.01)** **G 01 N 33/50 (2006.01)**
G 01 N 33/68 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2020-07-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-04-01**
- (86) Europæisk ansøgning nr.: **17165633.3**
- (86) Europæisk indleveringsdag: **2012-11-12**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-09-06**
- (30) Prioritet: **2011-11-12 US 201161559076 P**
- (62) Stamansøgningsnr: **12808926.5**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Massachusetts Institute of Technology, 77 Massachusetts Avenue , Cambridge, MA 02139, USA**
The Governors of the University of Alberta, 4000 Enterprise Square , 10230 Jasper Avenue, Edmonton, Alberta T5J 4P6, Canada
- (72) Opfinder: **KLAPOETKE, Nathan, 19795 Helix Drive 208, Ashburn, VA 20147, USA**
CHOW, Brian, Yichiun, 1616 Crown Point Lane, Cherry Hill, NJ 08003, USA
BOYDEN, Edward, 57 Clearwater Road, Chestnut Hill, MA 02467, USA
WONG, Gane, Ka-Shu, 9815 113th St NW, Edmonton, Alberta T5K 1N3, Canada
CHO, Yongku Peter, 125 South St., Apt 293, Vernon, CT 06066, USA
- (74) Fuldmægtig i Danmark: **HØIBERG P/S, Adelgade 12, 1304 København K, Danmark**
- (54) Benævnelse: **Kanalrhodopsiner til optisk kontrol af celler**
- (56) Fremdragne publikationer:
EP-A1- 2 112 510
WO-A1-2009/119782
WO-A2-03/084994
WO-A2-2007/024391
OFER YIZHAR ET AL: "Neocortical excitation/inhibition balance in information processing and social dysfunction", NATURE, vol. 477, no. 7363, 1 January 2011 (2011-01-01), pages 171-178, XP055056705, ISSN: 0028-0836, DOI: 10.1038/nature10360
Katrin Feldbauera ET AL: "Channelrhodopsin-2 is a leaky proton p", PNAS, 1 January 2009 (2009-01-01), XP055056624, Retrieved from the Internet: URL:http://www.pnas.org/content/106/30/12317.full.pdf [retrieved on 2013-03-14]

DESCRIPTION

[0001] This invention was made with government support under grants NIH 1DP2OD002002, NIH 1RC1MH088182, NIH 1R01NS067199, NIH 1R01DA029639, and NIH 1R01NS075421 from the National Institutes of Health; NSF DMS 0848804, NSF CAREER Award CBET 1053233, and NSF EFRI 0835878 from the National Science Foundation; a DARPA Living Foundries Early Career Translational Research Award, Wallace H. Coulter Foundation Department of Defense MPMC/CDMRP, Post-Traumatic Stress Disorder Concept Award Human Frontiers Science Program. The United States government has certain rights in the invention.

FIELD OF THE INVENTION

[0002] The invention, in some aspects relates to compositions and methods for altering conductance across membranes, and also relates to the use of exogenous light-activated ion channels in cells and subjects.

BACKGROUND OF THE INVENTION

[0003] Altering and controlling cell membrane and subcellular region ion permeability has permitted examination of characteristics of cells, tissues, and organisms. Light-driven pumps and channels have been used to silence or enhance cell activity and their use has been proposed for drug screening, therapeutic applications, and for exploring cellular and subcellular function.

[0004] Molecular-genetic methods for preparing cells that can be activated (e.g., depolarized) or inactivated (e.g., hyperpolarized) by specific wavelengths of light have been developed (see, for example, Han, X. and E. S. Boyden, 2007, PLoS ONE 2, e299). It has been identified that the light-activated cation channel channelrhodopsin-2 (ChR2), and the light-activated chloride pump halorhodopsin (Halo/NpHR), when transgenically expressed in cell such as neurons, make them sensitive to being activated by blue light, and silenced by yellow light, respectively (Han, X. and E. S. Boyden, 2007, PLoS ONE 2(3): e299; Boyden, E. S., et. al., 2005, Nat Neurosci. 2005 Sep;8(9):1263-8. Epub 2005 Aug 14.). Previously identified light-activated pumps and channels have been restricted to activation by particular wavelengths of light, thus limiting their usefulness.

SUMMARY OF THE INVENTION

[0005] The invention provides an isolated light activated ion channel polypeptide, comprising

an amino acid sequence of a wild-type or modified light-activated *Stigeoclonium helveticum* channel polypeptide, as defined in claim 1. The invention also provides a method of altering ion conductivity of a membrane, wherein the method is carried out *in vitro*, as defined in claim 2. The invention also provides a nucleic acid encoding the polypeptide, as defined in claim 5, and a vector comprising the nucleic acid, as defined in claim 7. The invention further provides a method of assessing the effect of a candidate compound on ion conductivity of a membrane, as defined in claim 9. The invention further provides the polypeptide, nucleic acid or vector for use in a method of treating a disorder in a subject, as defined in claim 10, and provides the polypeptide for use in a method of medical treatment of a subject, as defined in claim 11.

[0006] Therefore, the invention, in part, relates to isolated light-activated ion channel polypeptides and methods for their use. The invention also includes isolated nucleic acid sequences that encode light-driven ion channels of the invention as well as vectors and constructs that comprise such nucleic acid sequences. In addition, the invention in some aspects utilizes expression of light-activated ion channel polypeptides in cells, as well as providing methods for using the light-activated ion channels to alter conductance across membranes, and for use in treatment of disorders.

[0007] As noted above, the claimed invention includes a nucleic acid encoding the isolated light activated ion channel polypeptide of the invention, as defined in claim 5. At least one nucleic acid sequence encoding a light-driven ion channel can be incorporated into at least one target cell, subcellular region, or extracellular region, the ion channel functioning to change transmembrane passage of ions in response to a specific wavelength of light. Exposing an excitable cell that includes an expressed light-driven ion channel of the invention to a wavelength of light that activates the channel, may result in depolarization of the excitable cell. By contacting a cell that includes a light activated ion channel of the invention with particular wavelengths of light, the cell is depolarized. A plurality of light-activated ion channels activated by different wavelengths of light in overlapping or non-overlapping pluralities of cells may be used to achieve multi-color depolarization.

[0008] Channels of the invention can be genetically expressed in specific cells (e.g., using a virus or other means for delivery) and then used to control cells in intact organisms (including humans) as well as cells *in vitro*, in response to pulses of light. Given that these channels have different activation spectra from one another and from the state of the art (e.g., ChR2/VChR1), they also allow multiple colors of light to be used to depolarize different sets of cells in the same tissue, by expressing channels with different activation spectra genetically in different cells, and then illuminating the tissue with different colors of light.

[0009] Eukaryotic channelrhodopsins, include *Chloromonas subdivisa* (also referred to herein as: "ChR87"), *Chlamydomonas noctigama* (also referred to herein as: "Chrimson" or "Chr88"), and *Stigeoclonium helveticum* (also referred to herein as: "Chronos" or "ChR90") rhodopsin, and derivatives thereof. The present claimed invention uses *Stigeoclonium helveticum*. These channelrhodopsins, or derivatives thereof, can be used to depolarize excitable cells. These channelrhodopsins, or derivatives thereof, can also be used to modify the pH of cells, or to

introduce cations as chemical transmitters.

[0010] The ability to optically perturb, modify, or control cellular function offers many advantages over physical manipulation mechanisms, such as speed, non-invasiveness, and the ability to easily span vast spatial scales from the nanoscale to macroscale. One such approach is an opto-genetic approach, in which heterologously expressed light-activated membrane polypeptides such as a light activated ion channel of the invention, are used to move ions with various spectra of light.

[0011] As noted above, according to an aspect of the invention, methods of altering ion conductivity of a membrane are provided, as defined in claim 2. The methods include a) expressing in a membrane a light-activated ion channel polypeptide according to the invention and b) contacting the light-activated ion channel polypeptide with a light that activates the light-activated ion channel and alters the ion conductivity of the membrane, wherein the method is carried out *in vitro*. In some embodiments, the membrane is not a membrane in which the light-activated ion channel naturally occurs. In some embodiments, the light-activated ion channel is an isolated ion channel. In some embodiments, the membrane is in cell. In some embodiments, the cell is a neuronal cell and the method further comprises contacting the ion channel polypeptide with a light having a wavelength up to 660 nm under conditions suitable to produce a spike in the neuronal cell. In some embodiments, the light that activates the ion channel has a wavelength between 365 nm and 630 nm. In some embodiments, the light that activates the ion channel has a wavelength from 430 nm to 550 nm, and optionally, has a wavelength of 500 nm. In certain embodiments, contacting the polypeptide with a light having a wavelength greater than 650 nm does not activate the ion channel. In some embodiments, the cell is a neuronal cell and the method further includes contacting the ion channel polypeptide with a light having a wavelength between 430 nm and 550 nm in a manner to produce a spike in the neuronal cell. In some embodiments, the nucleic acid sequence encoding the light-activated ion channel polypeptide comprises the nucleic acid sequence set forth as SEQ ID NO:8. In certain embodiments, the amino acid sequence of the light-activated ion channel polypeptide comprises SEQ ID NO:7. In some embodiments, the amino acid sequence of the light-activated ion channel polypeptide comprises a modified *Stigeoclonium helveticum* light-activated ion channel sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to amino acids 61-295 of SEQ ID NO:7 and 95%, 96%, 97%, 98%, 99% or 100% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:7.

[0012] In certain embodiments, the membrane is a cell membrane. In some embodiments, the cell is a human cell. In some embodiments, the membrane is a cell membrane of a neuronal cell, a nervous system cell, a cardiac cell, a circulatory system cell, a visual system cell, or an auditory system cell. In certain embodiments, altering the ion conductivity of the membrane depolarizes the cell.

[0013] As noted above, according to another aspect of the invention, an isolated light activated ion channel polypeptide is provided, as defined in claim 1. The light-activated ion channel polypeptide includes an amino acid sequence of a wild-type or modified light-activated

Stigeoclonium helveticum channel polypeptide. In some embodiments, the light-activated ion channel polypeptide comprises an amino acid sequence of a wild-type or modified light-activated *Stigeoclonium helveticum* polypeptide and activating the ion channel comprises contacting the ion channel polypeptide with a light having a wavelength between 365 nm and 630 nm. In some embodiments, activating the ion channel includes contacting the ion channel polypeptide with a light having a wavelength from 430 nm to 550 nm, and optionally having a wavelength of 500 nm. In some embodiments, contacting the ion channel polypeptide with a light having a wavelength greater than 650 nm does not activate the ion channel. In certain embodiments, the nucleic acid sequence encoding the light-activated ion channel polypeptide comprises the nucleic acid sequence set forth as SEQ ID NO:8. In some embodiments, the amino acid sequence of the light-activated ion channel polypeptide comprises SEQ ID NO:7. In some embodiments, the amino acid sequence of the light-activated ion channel polypeptide comprises a modified *Stigeoclonium helveticum* light-activated ion channel sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to amino acids 61-295 of SEQ ID NO:7 and 95%, 96%, 97%, 98%, 99% or 100% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:7. In some embodiments, the light-activated ion channel polypeptide is expressed in a membrane. In certain embodiments, the membrane is mammalian cell membrane. In some embodiments, the cell is an excitable cell. In some embodiments, the cell is in a subject. In some embodiments, the membrane is a cell membrane of a neuronal cell, a nervous system cell, a cardiac cell, a circulatory system cell, a visual system cell, or an auditory system cell. In certain embodiments, altering the ion conductivity of the membrane depolarizes the cell.

[0014] As noted above, according to another aspect of the invention, a vector that includes a nucleic acid sequence that encodes any of the aforementioned light-activated ion channel polypeptides is provided, as defined in claim 5.

[0015] According to an aspect, which is described but not claimed, a cell that includes any of the aforementioned light-activated ion channel polypeptides is provided and the cell is not a cell in which the light-activated ion channel polypeptide naturally occurs. In some embodiments, the cell is a mammalian cell and in certain embodiments the cell is a human cell.

[0016] According to an aspect which is described but not claimed, methods of assessing the effect of a candidate compound on-ion conductivity of a membrane are provided. The methods include (a) contacting a test membrane comprising the isolated light-activated ion channel polypeptide of any one of the aforementioned embodiments with light under conditions suitable for altering ion conductivity of the membrane; (b) contacting the test membrane with a candidate compound; and (c) identifying the presence or absence of a change in ion conductivity of the membrane contacted with the light and the candidate compound compared to ion conductivity in a control cell contacted with the light and not contacted with the candidate compound; wherein a change in the ion conductivity in the test membrane compared to the control indicates an effect of the candidate compound on the ion conductivity of the test membrane. In some embodiments, the membrane is in a cell. In certain embodiments, altering the ion conductivity of the membrane depolarizes the cell. In some embodiments, a change is

an increase in ion conductivity of the membrane. In some embodiments, the change is a decrease in ion conductivity of the membrane.

[0017] According to another aspect of the invention, a light-activated ion channel polypeptide, a nucleic acid, or a vector, for use in a method of treating a disorder in a subject are provided, as defined in claim 10. The method includes (a) administering to a subject in need of such treatment, a therapeutically effective amount of a light-activated ion channel polypeptide or a nucleic acid or a vector of any one of the aforementioned embodiments, to treat the disorder, whereby said administration results in expression of the light-activated ion channel in a cell in the subject, and (b) contacting the cell with light and activating the light-activated ion channel in the cell under conditions sufficient to alter ion conductivity of a cell membrane, wherein altering the conductivity of the cell membrane treats the disorder. In some embodiments, altering the ion conductivity of the membrane depolarizes the cell.

[0018] According to an aspect which is described but not claimed, methods of performing a 2, 3, 4, 5 or more-color light ion channel activation assay in a population of cells are provided. The methods include (a) expressing a blue-light-activated ion channel in a first subpopulation of a population of cells; (b) expressing a red-light-activated ion channel in a second subpopulation of the population of cells, wherein the first and second subpopulations are non-overlapping subpopulations; (c) contacting the population of cells with a plurality of blue light test doses comprising combinations of blue light wavelength, pulse width, and power; (d) measuring transmembrane voltage deflection in a cell of the second subpopulation of cells contacted with the blue light test doses; (e) determining the test blue light dose comprising a maximum blue light power that activates the blue-light activated ion channel in first subpopulation of cells and results in a minimum sub-threshold transmembrane voltage deflection in the second subpopulation of cells; (f) contacting the population of cells with a plurality of blue light test doses comprising a lower power than the maximum blue light power of (e); (g) determining the blue light test doses of (f) that activate the blue-light activated ion channel; (h) contacting the population of cells with a plurality of red light test doses comprising combinations of red light wavelength, pulse width, and power, (i) determining a red light test dose comprising a red light power that activates the second subpopulation of cells; and (j) performing an activity assay comprising contacting the population of cells with the blue light test dose determined in (g) and the red light test dose determined in (i). In certain embodiments, the plurality of blue light test doses comprise wavelengths, pulse widths, and powers independently selected from between 400 nm and 500 nm, 1 ms and 5 ms, and 10 $\mu\text{W}/\text{mm}^2$ and 1.0 mW/mm^2 , respectively. In some embodiments, the red light test dose of (i) is the test dose comprising a minimum red light power that activates the second population of cells. In some embodiments, measuring the transmembrane voltage deflection in (d) comprises patch clamping a cell of the second population of cells and determining one or more voltage changes in the cell. In certain embodiments, the determining in (e) comprises altering the blue light dose by increasing the blue light power from 0.5 mW/mm^2 to 10 mW/mm^2 ; and measuring the sub-threshold transmembrane voltage deflection in the second subpopulation of cells. In some embodiments, the minimum sub-threshold voltage deflection is less than 15 mV, less than 10 mV, or less than 5 mV. In some embodiments, the maximum blue light power in

(e) is between 0.4 mW/mm^2 and 0.6 mW/mm^2 . In some embodiments, the blue light power in (g) is between $50 \text{ } \mu\text{W/mm}^2$ and 0.4 mW/mm^2 . In certain embodiments, the red-light activated ion channel comprises an amino acid sequence of a wild-type or modified light-activated *Chlamydomonas noctigama* polypeptide. In some embodiments, the nucleic acid sequence encoding the red light-activated ion channel polypeptide comprises the nucleic acid sequence set forth as SEQ ID NO:3. In some embodiments, the amino acid sequence of the red light-activated ion channel polypeptide comprises SEQ ID NO:2. In some embodiments, the amino acid sequence of the red light-activated ion channel polypeptide comprises a modified *Chlamydomonas noctigama* light-activated ion channel sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to amino acids 86-320 of SEQ ID NO:2 and 95%, 96%, 97%, 98%, 99% or 100% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:2. In certain embodiments, the amino acid sequence of the red light-activated ion channel polypeptide comprises SEQ ID NO:5. In some embodiments, the amino acid sequence of the red light-activated ion channel polypeptide comprises a modified *Chlamydomonas noctigama* light-activated ion channel sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to amino acids 86-320 of SEQ ID NO:5 and 95%, 96%, 97%, 98%, 99% or 100% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:5. In some embodiments, the blue-light activated ion channel comprises an amino acid sequence of a wild-type or modified light-activated *Stigeoclonium helveticum* polypeptide. In some embodiments, the nucleic acid sequence encoding the blue light-activated ion channel polypeptide comprises the nucleic acid sequence set forth as SEQ ID NO:8. In some embodiments, the amino acid sequence of the blue light-activated ion channel polypeptide comprises SEQ ID NO:7. In some embodiments, the amino acid sequence of the blue light-activated ion channel polypeptide comprises a modified *Stigeoclonium helveticum* light-activated ion channel sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to amino acids 61-295 of SEQ ID NO:7 and 95%, 96%, 97%, 98%, 99% or 100% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:7. In some embodiments, the plurality of red light test doses comprise wavelengths, pulse widths, and powers independently selected from between 600 nm and 740 nm, 1 ms and 5 ms, and 0.1 mW/mm^2 and 100 mW/mm^2 , respectively.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019]

Figure 1 shows a graph of channelrhodopsin photocurrents measured in cultured hippocampal neurons. Fig. 1A shows results using red light (660nm) peak photocurrent at 10 mW mm^{-2} for 1s illumination. ChR88 is the only red light sensitive channelrhodopsin with significant photocurrent at 660nm. Fig. 1B shows results using blue (4.23 mW mm^{-2}) or green (3.66 mW mm^{-2}) light peak photocurrent at equal photon flux for 5ms illumination. ChR87, ChR88, and ChR90 all have greater or comparable photocurrent than ChR2. Solid bar indicates blue light,

horizontal striped bar indicates green light.

Figure 2 is a graph showing action spectrum at equal photon dose at all wavelengths recorded in HEK293FT cells. ChR2 (470nm peak) and VChR1 (545nm peak) represent the existing channelrhodopsin color sensitivity range. ChR87 (515nm peak) and ChR90 (500nm peak) are blue green light sensitive channelrhodopsins. Whereas ChR88 (590nm peak) is the first red light sensitive natural channelrhodopsin.

Figure 3 provides example traces of optically-driven spikes in cultured hippocampal neurons. Fig. 3A shows red-light-driven spike trains at low frequency for Ch88. Generally ChR88 can reliably drive spikes up to 5Hz. However at higher frequency such as 20Hz, ChR88 desensitizes and/or causes depolarization block. Fig. 3B shows green-light-driven spike trains at high frequency for Ch90. Due to ChR90 fast tau off and peak photocurrent recovery kinetics, it is able to drive temporally precise spikes at the highest frequency a neuron is capable of mediating.

Figure 4 provides graphs showing channelrhodopsin kinetics measured in hippocampal neuron culture voltage clamped at -65mV. Fig. 4A shows single exponential channel turn-off kinetics based on 5 ms pulse. ChR90 has the fastest turn-off kinetics (3.5ms) observed across all natural channelrhodopsins. Fig. 4B shows peak photocurrent recovery ratio based on 1s illumination. ChR87 and ChR90 both have fast peak photocurrent recovery at around 70%. However ChR88 has slow recovery kinetics similar to ChR2.

Figure 5 provides a graph and traces showing Chrimson blue light crosstalk characterization in cultured neurons. Fig. 5A shows action spectrum of Chrimson and the blue light (470nm) wavelength used for illumination. Wavelength was chosen to minimize crosstalk. Fig. 5B provides representative traces from a single neuron at various illumination conditions. When the blue light power is doubled from 0.1 to 0.2 mW mm⁻² while the stimulation protocol is fixed as 5ms 5Hz, the voltage deflection is also doubled. However when the blue light power is fixed at 0.1 mW mm⁻² but the pulse duration is changed from 5ms to 1000ms, the crosstalk is changed from <5 mV to full spiking correspondingly. This means blue light crosstalk is a function of both light power and light pulse duration (total photon count).

Figure 6 provides graphs and traces illustrating Chronos and ChR2 blue light sensitivity in cultured hippocampal neurons. Fig. 6A is a spike irradiance curve for individual neurons. Fig. 6B shows lowest light power needed for single-cell 100% spike probability vs GFP fluorescence. Chronos (circles) is approximately 5 times more light sensitive than ChR2 (triangles) at a given (GFP) expression level. Fig. 6C provides example traces of Chronos spiking at various light powers. Fig. 6D illustrates that controls show no significant electrical differences between ChR2 and Chronos expressing neurons.

Figure 7 provides a graph and photomicrographic images illustrating the strategy used for slice characterization of Chronos and Chrimson. Fig. 7A shows illumination wavelength used for slice experiments. Fig. 7B is micrographic images showing histology for Chronos and Chrimson GFP fusion construct singly expressed in layer 2/3 visual cortex in mice.

Figure 8 provides graphs illustrating whole cell patch clamp characterization of Chrimson and Chronos blue and red light sensitivity in slice. Fig. 8A illustrates that red light elicits 100% spiking in Chrimson expressing neurons but not Chronos expressing neurons between 1-6.5 mW mm⁻². Fig. 8B shows that blue light at 0.2-0.5 mW mm⁻² can elicit 100% spiking in Chronos expressing cells but not Chrimson expressing cells. However full spiking crosstalk in Chrimson expressing cells can occur at powers higher than 0.6 mW mm⁻². Fig. 8C shows blue light crosstalk voltage of Chrimson expressing neurons.

Figure 9 provides example traces of current-clamped opsin-expressing neurons in layer 2/3 slice blue light 0.1 mW mm⁻², red light 1 mW mm⁻² expressing. No crosstalk was observed under red light for Chronos while minimal subthreshold (<5mV) crosstalk was observed under blue light for Chrimson.

Figure 10 provides example traces of voltage-clamped non-opsin-expressing neurons in layer 2/3 or 5, post-synaptic to opsin-expressing cells. Zero post-synaptic crosstalk was observed for both Chronos and Chrimson under red and blue light illumination respectively.

Chronos: blue light 0.13 mW mm⁻², red light 1.7 mW mm⁻².

Chrimson: blue light 0.37 mW mm⁻², red light 1.7 mW mm⁻².

Figure 11 provides a schematic diagram, photomicrographic image and traces illustrating paired-pulse illumination in slice that differentially express Chrimson and Chronos in separate neurons. Fig. 11A shows a triple plasmid in utero electroporation scheme to obtain non-overlapping expression of Chrimson and Chronos. Fig. 11B shows opsin expression in visual cortex no overlap of GFP and mO2 is observed ratio of Chronos to Chrimson labeling can be tuned by titrating Cre plasmid. Fig. 11C shows voltage-clamped non-opsin-expressing neuron in layer 2/3 paired-pulse stimulation to demonstrate different synapses are selectively driven by blue and red light. blue: 0.2 mW mm⁻²; red: 5 mW mm⁻². Arrows represent light application. First trace from top: first arrow indicates blue light, second arrow indicates red light; second trace from top: first arrow indicates red light, second arrow indicates blue light; third trace from top: both arrows represent red light; and fourth trace from top: both arrows represent blue light.

Figure 12 is a trace illustrating that Chrimson can drive spikes in the far-red (660 nm) using 5 ms pulses at 2.6 mW mm⁻² in cultured hippocampal neurons.

Figure 13 provides traces illustrating that the ChR88 K176R mutant has improved kinetics (13ms tau off) and can mediate high frequency spikes in cultured hippocampal neurons. Exemplar current clamped traces of a single ChR88 K176R expressing neuron are shown. Fig. 13A shows that ChR88 K176R can reliably drive spikes from 1 to 10 mW mm⁻² at 625nm 5Hz stimulation. Fig. 13B shows red light (625nm) driven spike trains at various frequency for ChR88 K176R. 1 mW mm⁻² light power is used for all frequencies. Fig. 13C shows current injection control to show the neuron is capable of spiking at the indicated frequencies.

Figure 14 provides graphs showing channelrhodopsin ion selectivity measured in HEK293FT

cells. ChR88 and ChR90 have comparable ion selectivity as ChR2. However ChR87 has less sodium (Na) current compared to calcium (Ca), proton (H), and potassium (K) current.

BRIEF DESCRIPTION OF THE SEQUENCES

[0020]

SEQ ID NO:1 is amino acid sequence from *Chlamydomonas noctigama*

MAELISSATRSIFAAGGINPWPNPYHHEDMGC GGMTPTGECFSTEWWC DPSYGLSD
AGYGYCFVEATGGYLVVGVEKKQAWLHSRGTPGEKIGAQCQWIAFSIAIALLT
FYGFSAWKATCGWEEVYVCCVEVLFVTLEIFKEFSSPATVYLSTGNHAYCLRYFEWLLS
CPVILIKLSNLSGLKNDYSKRTMGLIVSCVGMIVFGMAAGLATDWLKWLLYIVSCIY
GGYMYFQAAKCYVEANHSVPKGHCRMVVKLMAYAYFASWGSYPILWAVGPEGLL
KLSPYANSIGHSICDIIAKEFWTFLAHLRIKIHEHILIHGDIRKTTKMEIGGEEVEVEEF
VEEDEDVTHPTSNLANRNSFVIMAERMARGIDVRASLDRNGPMIESGRVILADT
DIFVTEMFKAQFAQLPAAIELIPALGADNALQLVQQASVLGGCDFVMVHPQFLKDNS
PSGLVARLRMMGQRVVAFGPANLRELIESCDVDAWIEAPPINLYQLRQVVAQMQLM
RRQAAMMGMMGGMKGGMSGMGMGMHAGSMWKQQQMMMQQDGSAMMMMPA
MQGGAASMRGSLISAQPGRQASLGGPQSVMMGSAMVGSNPLFGTAPSPLGSAVG
AEAMGHNL YGNQAAAGGIPAASAAADGTDVEMMQQLMSEIDRLKGELGEQDMPR.

SEQ ID NO:2: ChR88 coding amino acid sequence that includes residues 1-350 of SEQ ID NO:1

MAELISSATRSIFAAGGINPWPNPYHHEDMGC GGMTPTGECFSTEWWC DPSYGLSD
AGYGYCFVEATGGYLVVGVEKKQAWLHSRGTPGEKIGAQCQWIAFSIAIALLT
FYGFSAWKATCGWEEVYVCCVEVLFVTLEIFKEFSSPATVYLSTGNHAYCLRYFEWLLS
CPVILIKLSNLSGLKNDYSKRTMGLIVSCVGMIVFGMAAGLATDWLKWLLYIVSCIY
GGYMYFQAAKCYVEANHSVPKGHCRMVVKLMAYAYFASWGSYPILWAVGPEGLL
KLSPYANSIGHSICDIIAKEFWTFLAHLRIKIHEHILIHGDIRKTTKMEIGGEEVEVEEF
VEEDEDV.

SEQ ID NO:3 is a mammalian-codon optimized DNA sequence encoding ChR88 light-activated ion channel polypeptide

atggctgagctgacgcagcgcaccagatctctgttgcgcgcgagggcatcaacccttggcctaaccctaccaccagaggac
atgggctgtggaggaatgacacctacaggcgcgagtgctcagcaccgagtggtggtgtgacctcttaccggactgagcgcgagccgga
tacggatattgtcttgaggccacagcgcgctacctggtcgtgggagtgagagaagaagcagcgttggtgcacagcagaggcac
accaggagaaagatcgccgcgccaggtctccagtggtgattgtcttcagcatcgccatcgccctgctgacattctacggcttcagcgc
tggaaggccacttgcggttgaggagggtctacgtctgttcgctcaggtgctgttcgtgacctggagatcttcaaggagttcagcag
ccccgccacagtgatctgtaccggcaaccacgcctattgcctgcgctacttcgagtggtgctgtcttccccgtatcctgatcaa

gctgagcaacctgagcggcctgaagaacgactacagcaagcggaccatgggcctgacgtgtcttgcgtgggaatgatcgtgttcgg
catggcgcgagcagctggctaccgattggctcaagtggctgctgtatatcgtgtcttgcacatcagcggcgtacatgtacttccagccgc
caagtgtctacgtggaagccaaccacagcgtgcctaaaggccattgccgcatggtcgtgaagctgatggcctacgcttacttcgcctctt
ggggcagctaccaatctcttgggcagtgaggaccagaaggactgctgaagctgagccctacgccaacagcatcgccacagcatc
tgcgacatcatcgccaaggagtttggaccttctggccaccacctgaggatcaagatccacgagcacatctgatccacggcgaca
tccggaagaccaccaagatggagatcgaggcgcgagggtggaagtggagagttcgtggaggaggaggacgaggacacagtg

SEQ ID NO:4 is transmembrane region of ChR88 including residues 86-320 of SEQ ID NO:2
GTPGEKIGAQCQWIAFSIAIALLT FYGFSAWKATCGWEEVYVCCVEVLFVTLEIFKE
FSSPATVYLSTGNHAYCLRYFEWLLSCPVILIKLSNLSGLKNDYSKRTMGLIVSCVGM
IVFGMAAGLATDWLKWLLYIVSCIYGGYMYFQAAKCYVEANHSVPKGHCRMVVK
I MAYAYFASWGSYPILWAVGPEGLLKLSPYANSIGHSICDIIAKEFWTFLAHLRIKI

HEHILIH.

SEQ ID NO:5 is derived from Chr88 and includes K176R substitution

MAELISSATRSIFAAGGINPWPNPYHHEDMGC GGMTPTGECFSTEWWC DPSYGLSD
AGYGYCFVEATGGYLVVGVEKKQAWLHSRGTPGEKIGAQCQWIAFSIAIALLT
FYGFSAWKATCGWEEVYVCCVEVLVFTLEIFKEFSSPATVYLSTGNHAYCLRYFEWLLS
CPVILIRLSNLSGLKNDYSKRTMGLIVSCVGMIVFGMAAGLATDWLKWLLYIVSCIY
GGYMYFQAAKCYVEANHSVPKGHCRMVVKLMAYAYFASWGSYPILWAVGPEGLL
KLSPYANSIGHSICDIIAKEFWTFLAHLRIKIH EHLIHGDIRKTTKMEIGGEEVEVEEF
VEEDEDTV.

SEQ ID NO:6 is amino acid sequence from *Stigeoclonium helveticum*

METAATMTHAFISAVPSAEATIRGLLSAAAVVTPAADAHGETSNATTAGADHGC
FPHINHGTELQHKIAVGLQWFTVIVAIVQLIFYGWH SFKATTGWEEVYVCVIELVKCFIE
LFHEVDSPATVYQTNGGAVIWLRYSMWLLTCPVILIHLSNLTGLHEEYSKRTMTILV
TDIGNIVWGITA AFTKGPLKILFFMIGLFYGVTCFFQIAKVYIESYHTLPKGVCRKICKI
MAYVFFCSWLMFPVMFIAGHEGLGLITPYTSGIGHLILDLISKNTWGFLGHHLRVKIH
EHLIHGDIRKTTTINVAGENMEIETFVDEEEEGGVNHGTADLAHRASFQKMGDRLR
AQGVTVRASLDAHEVPPADEENKFAQKSAAANMPAYNPGKVILIVPDMSMVDYFR
DQFEQLPTRMELLPALGMDT.

SEQ ID NO:7 is Chr90 coding amino acid sequence that includes residues 1-325 of SEQ ID NO:6

METAATMTHAFISAVPSAEATIRGLLSAAAVVTPAADAHGETSNATTAGADHGC
FPHINHGTELQHKIAVGLQWFTVIVAIVQLIFYGWH SFKATTGWEEVYVCVIELVKCFIE
LFHEVDSPATVYQTNGGAVIWLRYSMWLLTCPVILIHLSNLTGLHEEYSKRTMTILV
TDIGNIVWGITA AFTKGPLKILFFMIGLFYGVTCFFQIAKVYIESYHTLPKGVCRKICKI
MAYVFFCSWLMFPVMFIAGHEGLGLITPYTSGIGHLILDLISKNTWGFLGHHLRVKIH
EHLIHGDIRKTTTINVAGENMEIETFVDEEEEGGV.

SEQ ID NO:8 is a mammalian-codon optimized DNA sequence encoding Chr90 light-activated ion channel polypeptide

atggaacagccgccacaatgacccagccttattctcagccgtgcctagcgcgaagccacaattagaggcctgctgagcgcgcg
agcagtggtgacaccagcagcagcagcgtcacggagaaaccttaacgccacaacagccggagccgatcacggtgcttccccac
atcaaccaggaaccgagctgcagcacaagatcgagtgaggactccagtggttcaccgtgatcgtggtatcgtgcagctcatcttct
acggttgccacagctcaaggccacaaccgctgggagggaggtctacgtctcgtgatcagctcgtcaagtgttcagcagctgtt
ccacgaggtcgacagccagccagctgtaccagaccaacggaggagccgtgatttggtgcggtacagcatgtggctcctgactt

gccccgtgatcctgatccacctgagcaacctgaccggactgcacgaagagtagcagcaagcggaccatgaccatcctggtgaccgac
atcggaacatcgtgtgggggatcacagcgcctttacaaaggccccctgaagatcctgttcttcagtcggcctgttctacggcgt
gactgtcttctccagatcgccaaggtgtatctcagagctaccacacctgcccgaaggcgtctgcggaagattgcaagatcatgg
cctacgtcttctctgctcttgctgatgttcccgtgatgttcacgcggacacagaggactggcctgatcacaccttacaccagcg
gaatcgggccacctgatcctggatctgatcagcaagaacctggggcttctggggccaccacctgagagtgaagatccacgagcaca
tctgatccacggcgacatccggaagacaaccaccatcaacgtggccggcgagaacatggagatcgagaccttcgtcgacgagga
ggaggaggaggagtg.

SEQ ID NO:9 is transmembrane region of Chr90 including residues 61-295 of SEQ ID NO:7
GTELQHKIAVGLQWFTVIVAIVQLIFYGWH SFKATTGWEEVYVCVIELVKCFIELFHE
VDSPATVYQTNGGAVIWLRYSMWLLTCPVILIHLSNLTGLHEEYSKRTMTILVTDIG
NIVWGITA AFTKGPLKILFFMIGLFYGVTCFFQIAKVYIESYHTLPKGVCRKICKIMAY
VFFCSWLMFPVMFIAGHEGLGLITPYTSGIGHLILDLISKNTWGFLGHHLRVKIH EHLIH
IH.

SEQ ID NO:10 is amino acid sequence from *Chloromonas subdivisa*

MSRLVAASWLLALLLCGITSTTTASSAPAASSTDGTA AAVSHYAMNGFDELAKGA
VVPEDHFVCGPADKCYCSAWLHSHGSKEEKTAFTVMQWIVFAVCIISLLFYAYQTW

RATCGWEEVYVTIIELVHVCFGLWHEVDSPCTLYLSTGNMVLWLRYA EWLLTCPVI
 LIHLSNLTGMKNDYNKRTMALLVSDVGCIVWGTTAALSTDFVKIIFFLGLLYGFYTF
 YAAAKIYIEAYHTVPKGICRQLVRLQAYDFFFTWSMFPILFMVGPEGFGKITAYSSGI
 AHEVCDLLSKNLWGLMGHFIRVKIHEHILVHGNITKKTKVNVAGDMVELDTYVDQ
 DEEHDEGTIDRGTQELANRHSFVVMRENMRAGVDVRASLGIDIDGTEMTKAGNMN
 GTLEPGRILCVPDMSLVDFREQFSQMPVPFEVVPALGPEVALQLVQQALSIGGANY
 IDYVM.

SEQ ID NO:11 ChR87 coding amino acid sequence that includes residues 1-346 of SEQ ID NO:10

MSRLVAASWLLALLLCGITSTTTASSAPAASSTDGTAAA AVSHYAMNGFDELA KGA
 VVPEDHFVCGPADKCYCSAWLHSHGSKEEKTAFTVMQWIVFAVCIISLLFYAYQTW
 RATCGWEEVYVTIIELVHVCFGLWHEVDSPCTLYLSTGNMVLWLRYA EWLLTCPVI
 LIHLSNLTGMKNDYNKRTMALLVSDVGCIVWGTTAALSTDFVKIIFFLGLLYGFYTF
 YAAAKIYIEAYHTVPKGICRQLVRLQAYDFFFTWSMFPILFMVGPEGFGKITAYSSGI
 AHEVCDLLSKNLWGLMGHFIRVKIHEHILVHGNITKKTKVNVAGDMVELDTYVDQ
 DEEHDEG.

SEQ ID NO:12 is a mammalian-codon optimized DNA sequence encoding ChR87 light-activated ion channel polypeptide

atgagcagactggcgcgcttctggtgctggtctctctctctgcggaattaccagcacaacaacagcctctagcgcgccagcag
 cttctctacagacggaacagccgccgcagcagtgctcactacgcatgaacggcttcgacgagctggctaaaggagccggtggtgc
 cagaagaccactttgtctgcccagccgacaagtgtattgtcgcgttggtgcacagccacggaagcaaggaggagaagacc
 gccttcacgctcatgagtgatggttgcgcgtctgcatcatcagcctgctgttctacgcctaccagactggagggtacttgcggtt
 gggaggagggtgtacgtgaccatcagcagctggtccagctgctcctggactctggcacgaggtcgatagccctgtacctgtacctg
 agcacaggcaacatggtcctctggctgagatacgcgagtggtgctgacttgccccgtgactctgatccacctgagcaacctgaccg
 gcatgaagaacgactacaacaagcggaccatggccctgctggtgtcagacgtgggctgtatcgtgtgggaacaacagccgcccctg
 agcaccgatttctgaagatcattcttcttcttctggcctgctgtacggcttctacacctctacgccgccgaagatctacatcgagg
 cctaccacaccgtgcccgaaggcatttctagacagctcgtgcggtgcaggcctacgacttcttcttacttgagcatgttccccatcc
 tgttcatgtgcccagagggaaltcggaagatcaccgcctacagcagcggaatcgccacgaagtgtgcgatctgtgagcaag
 aacctctggggcctgtatggccacttcacgcgtgaagatccacgagcacatcctggtgcagggcaacatcaccaagaagaccaa
 ggtcaacgtggccgcatggtggaactggacacctacgtggaccaggacgaggaacacgacgagga.

SEQ ID NO:13 is transmembrane region of ChR87 including residues 81-315 of SEQ ID NO:11

GSKEEKTAFTVMQWIVFAVCIISLLFYAYQTW RATCGWEEVYVTIIELVHVCFGLWH
 EVDSPCTLYLSTGNMVLWLRYA EWLLTCPVILIHLSNLTGMKNDYNKRTMALLVSD
 VGCIVWGTTAALSTDFVKIIFFLGLLYGFYTFYAAAKIYIEAYHTVPKGICRQLVRLQ
 AYDFFFTWSMFPILFMVGPEGFGKITAYSSGIAHEVCDLLSKNLWGLMGHFIRVKIHE
 HILVH.

SEQ ID NO:14 amino acid sequence for *Neochlorosarcina* sp. Rhodopsin. This light-activated ion channel is referred to herein as ChR62.

MADFWVQGAGNGGPSAMVSHYPNGSVLLESSGSCYCEDWYTSRGNHVEHSLSNAC
 DWFAFAISVIFLVYYAWAFNSSVGWEEIYVCTVELIKVSIDQFLSSNSPCTLYLSTG
 NRVLWIRYGEWLLTCPVILIHLSNVTGLKDNYSKRTMALLVSDIGTIVFGVTSAMCT
 GYPKVIFFILGCCYGANTFFNAAKVYLEAHTLPKGSCRTLIRLMAYTYASWGMFP
 ILFVLGPESFGHMNMYQSNIHTVIDLMSKNIWGMGLGHFLRHKIREHILIHGDLRTTT
 TVNVAGEEMQVETMVAEDAETTV.

SEQ ID NO:15 is the mammalian codon-optimized DNA sequence for the *Neochlorosarcina* rhodopsin. This light-activated ion channel is referred to herein as ChR62.

atggccgacttctgtggtgaggagctggaaacggaggaccaagcgccatggtgtccactacccaatggcagcgtgctgctgga
 gagctccggcagctgctactgtgaagactgtatattctcggggcaaccagtgaggacattctctagtaatgcttgcgattggtcgc
 ctttgcctatcagcgtgatttctggtgtactatgctggcgccgttttaactctagtgtgggctgggaggaaatctacgtgtgcaccgtgg
 agctgatcaaggtgagcattgatcagttcctgagctccaactctcctgtaccctgtacctgagtacagggaatagggtgctgtggatca
 gatatggcgaatggctgctgacttgcagtgatcctgattcacctgtccaacgtgacagggtgaggaacaattactctaaacgcacta

tggctctgctggtgagtatacgggaccatcgtgttcggcgtgacttctgcatgtgcaccggataccccaaagtatcttcttattctg
ggctgctgttatggagctaacacattcttaatgccgctaaggtgtacctggaggcccaccatacactgcctaaaggctctttaggact
ctgatcagactgatggcctatactactatgctagttgggaatgtccccattctgtttgtgctgggacctgagagcttcggccacatga
acatgtaccagtcacaatatcgccataccgtgattgacctgatgtccaagaacatctggggaatgctggggcactttctgcggcataaa
attcgcgagcacatctgattcatggagatctgcggaccacaactaccgtgaatgtggctggggaggaaatgcaggtggaacaatg
gtggccgctgaggacgccgatgaaacaactgtg.

SEQ ID NO:16 is the amino acid sequence for *Heterochlamydomonas inaequalis* rhodopsin. This light-activated ion channel is referred to herein as Chr93.

MGGIGGGGIQPRDYSYGANGTVCVNPDVCFCLDWQQPFGSNMENNVSQGFQLFTIA
LSACILMFYAYEWYKATCGWEEIYVCVEMSKICIELVHEYDTPFCLYLATGSRVLW
LRYAEWLMTCPVILIHLSNITGLTDYNNKRTMVLMSDIGCIVFGATAAFANEGYVK
CACFLGMAWGMNTFYNAKVYYESYVLVPSGICKLLVAVMAGLYYVSWSLFPIL
FAIGPEGFGVISLQASTIGHTIADVLSKNMWGLMGHFLRVQIYKHILLHGNIRKPIKLH
MLGEEVEVMALVSEEGEDTV.

SEQ ID NO:17 is the mammalian codon-optimized DNA sequence for the *Heterochlamydomonas inaequalis* rhodopsin, this light-activated ion channel is referred to herein as Chr93.

atgggaggaattggcggaggcgcattcagcctagagactacagctacggcgccaacggaacagtctgcgtgaaccccgacgtct
gcttctgtctggattggcagcagcccttcggcttaacatggagaacaacgtgtcccagggtccagctgtttaccatcgccctgagc
gcctgcacctgatgtttacgcctacgagtggtacaaggccacttgcggtgggaggagatctacgtctgcgtggtggagatgagca
agatttgcacgagctggtgcacgagtagcacacccccctttgctgtacctggccaccggcagcagagtcctctggctgagatagc
cgagtggctcatgacttgccttcgtatcctgacacctgagcaacatcaccggactgggcaccgactacaacaagcggaccatggt
gctcctgatgagcgacatcggttgcacgtgttcggcgccacagcagcattcgccaacgagggtacgtgaagtgcgcttgttctcgtg

tgggcatggcttggggcatgaacaccttctacaacgccgccaaggtgtactacgagagctacgtgctggtgccctccggaatttgcaa
gctgctggtggccgtgatggccgactgtactacgtgtcttggagcctgttccccatcctgtttgccatcgcccgagggaattggcgt
gatcagcctgcaggccagcaccattggccacacaatcgccgacgtgctgagcaagaacatgtggggcctgatggccacttctcgc
gggtgcagatctacaagcacatctgtgcacggcaacatccggaagcctatcaagctgcacatgctgggagggaggtggaagtg
atggctctggtgtccgaggaggagaggataccgtg.

SEQ ID NO:18 is the mammalian codon-optimized DNA sequence that encodes the wild-type Channelrhodopsin-2, (see: Boyden, E. et al., *Nature Neuroscience* **8**, 1263 - 1268 (2005) and Nagel, G., et al. *PNAS* November 25, 2003 vol. 100 no. 24 13940-13945), also referred to herein as Chr2:

atggactatggcggcgtttgtctgccgtcggacgcgaactttgttctgactaatcctgtggtggtgaacgggtccgtcctggtccctg
aggatcaatgttactgtgccgatggattgaatctcgcggcacgaacggcgctcagaccgcgtcaaatgtcctgcagtggttgcagc
aggattcagcattttctgctgctgatgttctatgcctaccaaaacctggaatctacatcgcggtgggaggagatctatgtgtgcgccattgaa
atggttaaggtgattctcgagttctttttagtttaagaatccctctatgctctaccttgccacaggacaccgggtgcagtggtgcgctat
gcagagtggctgctcacttgtcctgtcctctatccactgagcaacctcaccggcctgagcaacgactacagcaggagaacctggtg
gactcctgtctcagacatcgaggactatcgtgtggggggctaccagcgccatggcaaccggctatgttaagtcattcttcttctgttgg
attgtgctatggcgcgaacacattttcacgcgcgcaaaagcatatcgagggtatcatactgtgccaagggtcggtgcgcggcaggt
cgtgaccggcatggcatggctgttttcgtgagctggggtatgtcccaattctctcattttggggcccgaagggtttggcgctcctgagcg
tctatggctccaccgtaggtgcacagattatgatctgatgagtaaaattgttgggggtgttgggacactacctgcgcgtcctgatcca
cgagcacatattgattcacggagatatccgcaaaaccaccaactgaacatcgcggaacggagatcgaggtcgagactctcgtcga
agacgaagccgaggccggagccgtg.

SEQ ID NO: 19 is the amino acid sequence of the wild-type Channelrhodopsin-2, (see: Boyden, E. et al., *Nature Neuroscience* **8**, 1263 - 1268 (2005) and Nagel, G., et al. *PNAS* November 25, 2003 vol. 100 no. 24 13940-13945), also referred to herein as Chr2:

MDYGGALSAVGRELLFVTNPVVVNGSVLPEDQCYCAGWIESRGTNGAQTASNVL
QWLAAGFSILLMLFYAYQTWKSTCGWEEIYVCAIEMVKVILEFFFEFKNPSMLYLAT
GHRVQWLRVLAEWLLTCPVILIHLSNLTGLSNDYSRRTMGLLVSDIGTIVWGATSAM
ATGYVKVIFFLGLCYGANTFFHAAKAYIEGYHTVPKGRRCRQVVTGMAWLFFVSW
GMFPILFILGPEGFVLSVYGSTVGHTIIDLMSKNCWGLLGHYLRVLIHEHILIHGDIR
KTTKLNIGGTEIEVETLVEDEAEAGAV.

SEQ ID NO:20 is the DNA sequence of the 'ss' signal sequence from truncated MHC class I antigen: gtcccggtgcacgctgctcctgctgttggcagccgccctggctccgactcagacgcgggcc.

SEQ ID NO:21 is the amino acid sequence of the 'ss' signal sequence from truncated MHC class I antigen: MVPCTLLLLLAAALAPTQTRA.

SEQ ID NO:22 is the DNA sequence of the ER export sequence (also referred to herein as "ER2": ttctgctacgagaatgaagtg.

SEQ ID NO:23 is the amino acid sequence of the ER export sequence (also referred to herein as "ER2": FCYENEV.

SEQ ID NO:24 is the DNA sequence of KGC, which is a C terminal export sequence from the potassium channel Kir2.1: aaatccagaattacttctgaaggggagtatatccctctggatcaaataagacatcaatgtt.

SEQ ID NO:25 is the amino acid sequence of KGC, which is a C terminal export sequence from the potassium channel Kir2.1: KSRITSEGEYIPLDQIDINV.

DETAILED DESCRIPTION

[0021] The invention provides an isolated light activated ion channel polypeptide as defined in claim 1. The present application describes the expression in cells of light-driven ion channel polypeptides that can be activated by contact with one or more pulses of light, which results in strong depolarization of the cell. Light-activated channels of the invention, also referred to herein as light-activated ion channels, can be expressed in specific cells, tissues, and/or organisms and used to control cells *in vivo*, *ex vivo*, and *in vitro* in response to pulses of light of a suitable wavelength. Light-activated ion channel polypeptides derived from *Stigeoclonium* rhodopsin sequences have now been identified and characterized as being activated by light having a wavelength between 365 nm and 630 nm.

[0022] The light-activated ion channels of the invention are ion channels and may be expressed in a membrane of a cell. An ion channel is an integral membrane protein that forms a pore through a membrane and assist in establishing and modulating the small voltage gradient that exists across the plasma membrane of all cells and are also found in subcellular membranes of organelles such as the endoplasmic reticulum (ER), mitochondria, etc. When a light-activated ion channel of the invention is activated by contacting the cell with appropriate light, the pore opens and permits conductance of ions such as sodium, potassium, calcium, etc. through the pore.

[0023] Light-activated channels may be used to modify the transmembrane potential (and/or ionic composition) of cells (and/or their sub-cellular regions, and their local environment). For example, the use of inwardly rectifying cationic channels will depolarize cells by moving

positively charged ions from the extracellular environment to the cytoplasm. Under certain conditions, their use can decrease the intracellular pH (and/or cation concentration) or increase the extracellular pH (and/or cation concentration). In some embodiments, the presence of light-activated ion channels in one, two, three, or more (e.g. a plurality) of cells in a tissue or organism, can result in depolarization of the single cell or the plurality of cells by contacting the light-activated ion channels with light of suitable wavelength.

Stigeoclonium-derived Light-activated Ion Channels

[0024] The claimed invention is based on an isolated light activated ion channel polypeptide comprising an amino acid sequence of a wild-type or modified light-activated *Stigeoclonium helveticum* channel polypeptide, as defined in claim 1.

[0025] When expressed in a cell, light-activated ion channels of the invention identified having a *Stigeoclonium* light-activated ion channel sequence or a derivative thereof, can be activated by contacting the cell with light having a wavelength between about 365 nm and 630 nm, between 430 nm and 550 nm; and in some embodiments, a peak activation may occur upon contact with light having a wavelength of 500 nm. Examples of these light-activated ion channels include ChR90 (also referred to herein as Chronos) and functional derivatives thereof.

[0026] Contacting an excitable cell that includes a *Stigeoclonium-derived* light-activated ion channel of the invention with a light in the activating range of wavelengths strongly depolarizes the cell. Exemplary wavelengths of light that may be used to depolarize a cell expressing a *Stigeoclonium-derived* light-activated ion channel of the invention, include wavelengths from at least about 365 nm, 385 nm, 405 nm, 425 nm, 445 nm, 465 nm, 485 nm, 505 nm, 525 nm, 545 nm, 565 nm, 585 nm; 605 nm, and 630 nm, including all wavelengths therebetween. In some embodiments, *Stigeoclonium-derived* light-activated ion channels of the invention have a peak wavelength sensitivity in of 500 nm.

[0027] In some embodiments, a *Stigeoclonium-derived* light-activated ion channel can drive temporally precise spikes with 1-5ms pulse width at 50uW/mm² to >10mW/mm² in neurons at "optimal wavelength" in slice and cultured cells; and can stimulate at frequency >100Hz at "optimal wavelength". As used herein an optimal wavelength for a *Stigeoclonium-derived* light-activated ion channel may be a wavelength between 430nm and 550nm.

[0028] Light-activated ion channels of the invention such as ChR90 and derivatives thereof can be used to depolarize excitable cells in which one or more light-activated ion channels of the invention are expressed. In some embodiments, *Stigeoclonium-derived* light-activated ion channels of the invention can be expressed in a sub-population of cells in a cell population that also includes one or more additional subpopulations of cells that express light-activated ion channels that are activated by wavelengths of light that do not activate a *Stigeoclonium-derived*

light-activated ion channel of the invention.

[0029] *Stigeoclonium-derived* light-activated ion channels of the invention permit ion conductance and depolarization when contacted under suitable conditions with an appropriate wavelength of light. As will be understood by those in the art, the term "depolarized" used in the context of cells means an upward change in the cell voltage. For example, in an excitable cell at a baseline voltage of about -65 mV, a positive change in voltage, e.g., up to 5, 10, 15, 20, 30, 40, or more millivolts (mV) is a depolarization of that cell. When the change in voltage is sufficient to reach the cell's spike initiation voltage threshold an action potential (e.g. a spike) results. When a cell is depolarized by activating a light-activated ion channel of the invention with an appropriate wavelength of light, the cell voltage becomes more positive than the baseline level, and an incoming signal may more easily raise the cell's voltage sufficiently to reach the threshold and trigger an action potential in the cell. It has been discovered that by contacting a cell expressing a *Stigeoclonium-derived* light-activated ion channel of the invention with light in the range between about 365 nm and 630 nm the voltage of the cell becomes less negative by as much as at least 20, 30, 40, 50, 60, 70, 80, 90, 100, mV, (depending on cell type). As used herein, the term "activate" when used in reference to a light-activated ion channel of the invention, means to open the channel making it permissive to ion conduction through the channel.

[0030] Specific ranges of wavelengths of light that in some embodiments of the invention are useful to activate ion channels of the invention are provided and described herein. It will be understood that a light of appropriate wavelength for activation and will have a power and intensity appropriate for activation. It is well known in the art that light pulse duration, intensity, and power are parameters that can be altered when activating a channel with light. Thus, one skilled in the art will be able to adjust power, intensity appropriately when using a wavelength taught herein to activate a light-activated ion channel of the invention. A dose light that contacts a light-activated ion channel of the invention may be determined based on the wavelength, pulse length, and power of the light that contacts the light-activated ion channel. Thus, as a non-limiting example, a dose may have a wavelength of 550 nm, a 4 ms pulse length, and a 0.5 mW/mm² power and another light dose may have a wavelength of 550 nm, a 3 ms pulse length and a 0.5 mW/mm² power. Those skilled in the art will understand methods to select a dose of light by independently selecting a wavelength, a pulse length, and a power for the light with which a light-activated ion channel of the invention is contacted. In some embodiments, wavelength and pulse length may be held steady, and power incrementally increased to examine activation parameters of a light-activated ion channel of the invention. Similarly, in certain embodiments of the invention may include incremental wavelength increases while pulse length and power are held steady; or incremental pulse length increases while wavelength and power are held steady. In some embodiments of the invention two or more of wavelength, pulse length, and power of a light may be incrementally altered to examine the effect on activation of a light-activating ion channel of the invention.

[0031] A benefit of a light-activated ion channel of the invention is the ability to "tune" the light-activated ion channel's response using appropriate illumination variables (e.g., wavelength,

intensity, duration, etc.) (also referred to herein as dose) to activate the channel. Methods of adjusting illumination variables are well-known in the art and representative methods can be found in publications such as: Lin, J., et al., *Biophys. J.* 2009 Mar 4;96(5):1803-14; Wang, H., et al., 2007 *Proc Natl Acad Sci U S A.* 2007 May 8;104(19):8143-8. Epub 2007 May 1. Thus, it is possible to utilize a narrow range of one or more illumination characteristics to activate a light-activated ion channel of the invention. The expression of light-activated ion channels that are activated by different wavelengths of light in distinct, separate, subpopulations in a cell population can permit application of different illumination parameters to the population with an effect of differentially activating the different subpopulations through the use specific wavelengths of light. Thus, permitting controlled activation of a mixed population of light-activated channels.

[0032] The claimed invention provides a nucleic acid as defined in claim 5 and a vector as defined in claim 7. Thus, the invention, in part, includes isolated nucleic acids comprising sequences that encode light activated ion channels of the invention as well as vectors and constructs that comprise such nucleic acid sequences. Disclosed but not claimed is the expression of polypeptides encoded by the nucleic acid sequences, in cells, tissues, and organisms.

[0033] Not all channelrhodopsins can be expressed in cells and utilized in this fashion, because many do not traffic properly and/or function in mammalian cells.

[0034] Light-activated channels can be used to modify the transmembrane potential (and/or ionic composition) of cells (and/or their sub-cellular regions, and their local environment). In particular, the use of inwardly rectifying cationic channels will depolarize cells by moving positively charged ions from the extracellular environment to the cytoplasm. Under certain conditions, their use can decrease the intracellular pH (and/or cation concentration) or increase the extracellular pH (and/or cation concentration).

[0035] Compared to natural gene sequences conventionally used to depolarize neurons, Chronos has demonstrably improved photocurrent generation at all illumination wavelengths except for red wavelength. In addition Chronos can depolarize cells in response to <5ms pulse of 50-100 $\mu\text{W mm}^{-2}$ of blue or green light with sufficient spectral independence from most green or red channelrhodopsins such as ChR87 or Chrimson, thus permitting multiple colors of light to be used to depolarize different sets of cells in the same tissue, simply by expressing pumps with different activation spectra genetically in different cells, and then illuminating the tissue with different colors of light. In a non-limiting example of an embodiment, one set of cells in a tissue, for example excitatory neurons, express Chrimson, and a second set express Chronos, illuminating the tissue with 630 nm light will preferentially depolarize the first set, and illuminating the tissue with 470 nm light at low powers (<5 mW mm^{-2}) will preferentially depolarize the second set. Other pairs of targets that could be modulated with two colors of light in the same illumination area include, but are not limited to two projections to/from one site, or combinations of the cell, its projections, and its organelles, given the ability to target the

molecule sub-cellularly.

[0036] It has been identified that light-activated ion channels of the invention are, in some embodiments of the invention, activated at different wavelengths than previously identified light-activated ion channels. Thus, light-activated ion channels of the invention can be used in either alone, using a selective light spectrum for activation and depolarization and can also be used in combination with other light-activated ion channels that utilize different wavelength of light for activation and depolarization, thus allowing two, three, four, or more different wavelengths of light to be used to depolarize different sets or subpopulations of cells in a tissue or organism by expressing channels with different activation spectra in different cells and then illuminating the tissue and/or organism with the appropriate wavelengths of light to activate the channels and depolarize the cells.

[0037] A light-activated ion channel from *Chlamydomonas noctigama* or a derivative thereof may be used in conjunction with a light-activated ion channel from *Stigeoclonium helveticum* or a derivative thereof. The two light-activated ion channels are sensitive to and can be activated with different wavelengths of light than each other. As described herein, certain light-activated ion channels of the invention can depolarize cells in strong response to light with sufficient spectral independence from that of other light-activate ion channels of the invention, thus allowing multiple colors of light to be used to depolarize different sets of cells in the same tissue, by expressing channels with different activation spectra genetically in different cells, and then illuminating the tissue with different colors of light in suitable dose to activate one type of light-activated ion channel but not the other type of light-activated ion channel. In a non-limiting example, if a first subset of cells in a tissue (e.g., excitatory neurons) express ChR88, and a second subset express ChR90 light-activated ion channels of the invention, then illuminating the tissue with a dose of light such as 625nm, 2 mW/mm² will preferentially depolarize/drive spike in the first subset (ChR88), and illuminating the tissue with a dose of light such as 470 nm 0.2 mW/mm² light will preferentially depolarize/drive spike in the second subset (ChR90). Other pairs of targets that could be modulated with two colors of light in the same illumination area include, but are not limited to two projections to/from one site, or combinations of the cell, its projections, and its organelles, given the ability to target the molecule sub-cellularly.

Taxonomy and sequence sources

[0038] In particular, the present invention includes, in part, novel light-activated ion channels. These may be used to depolarize cells. One or more newly identified light-activated ion channels may be expressed in cells.

[0039] Light-activated ion channels of the invention have amino acid sequences derived from *Stigeoclonium* rhodopsins that are naturally expressed in the genus *Stigeoclonium helveticum*. *Stigeoclonium helveticum* are green algae and can be found in fresh water environments. The invention makes use of isolated wild-type or modified nucleic acid and/or amino acid

channelrhodopsin sequences from a *Stigeoclonium helveticum*.

[0040] In the isolated light activated ion channel polypeptide of the claimed invention, the isolated light activated ion channel polypeptide comprises an amino acid sequence of a wild-type or modified light-activated *Stigeoclonium helveticum* channel polypeptide, wherein the amino acid sequence of the light-activated ion channel polypeptide comprises SEQ ID NO: 7 or the amino acid sequence of the light-activated ion channel polypeptide comprises a modified *Stigeoclonium helveticum* light-activated ion channel sequence having at least 70% identity to amino acids 61-295 of SEQ ID NO:7 and 95% identity to the remaining amino acids in the sequence set forth as SEQ ID NO:7. A modified light-activated ion channel polypeptide (also referred to as a derivative of a light-activated ion channel) versus a naturally occurring light activated ion channel may be altered by an substituting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids, by an insertion and/or deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids at one or several positions. Both a wild-type light-activated ion channel polypeptide and derivatives thereof may have an identity of at least 75%, 80%, 85%, 90%, 95%, or 100%, with the sequence of the transmembrane region of the wild-type light-activated ion channel polypeptide, as long as they retain channel functionality. For ChR87, which is described but not claimed, the amino acid sequence of the transmembrane region is set forth as SEQ ID NO:13, which includes amino acid residues 81-315 of SEQ ID NO:11. For ChR88, which is described but not claimed, the amino acid sequence of the transmembrane region is set forth as SEQ ID NO:4, which includes amino acid residues 86-320 of SEQ ID NO:2. For ChR90, the amino acid sequence of the transmembrane region is set forth as SEQ ID NO: 9, which includes amino acid residues 61-295 of SEQ ID NO:7.

[0041] In contrast, the level of identity between a derivative or modified light-activated ion channel of the invention and the wild-type from which it is derived may be more constrained to maintain the function of the light-activated ion channel. The amino acid sequence of a non-transmembrane region of a derived or modified light-activated ion channel of the invention, have at least 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of the wild-type light-activated ion channel polypeptide from which they are derived.

[0042] Thus, for example, in some embodiments, a light-activated ion channel of the invention may be a derivative of ChR90 and have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the non-transmembrane regions of the wild-type polypeptide sequence (SEQ ID NO:7) of the light-activated ion channel polypeptide from which it is derived. As used herein, the term "identity" refers to the degree of relatedness between two or more polypeptide sequences, which may be determined by the match between the sequences. The percentage is obtained as the percentage of identical amino acids in two or more sequences taking account of gaps and other sequence features. The identity between polypeptide sequences can be determined by means of known procedures. Algorithms and programs are available and routinely used by those in the art to determine identity between polypeptide sequences. Non-limiting examples of programs and algorithms include BLASTP, BLASTN and FASTA (Altschul et al., NCB NLM NIH Bethesda Md. 20894; Altschul et al., 1990), Online BLAST programs from the National Library of Medicine are available, for example, at

blast.ncbi.nlm.nih.gov/Blast.cgi.

[0043] One skilled in the art will understand that light-activated ion channels of the invention can be identified based on sequence similarity or homology to a light-activated ion channel disclosed herein. It will be understood that additional light-activated ion channels may be identified using sequence alignment with one of the light-activated ion channels or derivatives thereof identified herein.

[0044] Light-activated ion channels of the invention are transmembrane channel polypeptides that use light energy to open, permitting ion conductance through their pore, thus altering the potential of the membrane in which they are expressed. A non-limiting example of an ion that can be moved through a pore of the invention includes a sodium ion, a potassium ion, a calcium ion, a proton, etc. Routine methods may be used to measure different ion currents for light-activated ion channels of the invention. Light-activated ion channels of the invention can be activated by sustained light and/or by light pulses and by permitting ion conductance upon activation, light-activated ion channels of the invention can depolarize cells and alter the voltage in cells and organelles in which they are expressed.

[0045] The wild-type and modified (derived) *Chloromonas subdivisa*, *Chlamydomonas noctigama*, *Stigeoclonium helveticum* rhodopsin nucleic acid and amino acid sequences described and used herein are "isolated" sequences. As used herein, the term "isolated" used in reference to a polynucleotide, nucleic acid sequence, or polypeptide sequence of a rhodopsin, means a polynucleotide, nucleic acid sequence, or polypeptide sequence that is separate from its native environment and present in sufficient quantity to permit its identification or use. Thus, an isolated polynucleotide, nucleic acid sequence, or polypeptide sequence of the invention is a polynucleotide, nucleic acid sequence, or polypeptide sequence that is not part of, or included in its native, wild-type cell or organism. For example, a nucleic acid or polypeptide sequence may be naturally expressed in a cell or organism of a member of the *Chloromonas* genus, but when the sequence is not part of or included in a *Chloromonas* cell or organism it is considered to be isolated. Similarly, a nucleic acid or polypeptide sequence may be naturally expressed in a cell or organism of a member of the *Chlamydomonas* genus, but the sequence is not part of or included in a *Chlamydomonas* cell or organism, it is considered to be isolated. Similarly, a nucleic acid or polypeptide sequence may be naturally expressed in a cell or organism of a member of the *Stigeoclonium* genus, but the sequence is not part of or included in a *Stigeoclonium* cell or organism, it is considered to be isolated. Thus, a nucleic acid or polypeptide sequence of a *Chloromonas*, *Chlamydomonas*, *Stigeoclonium*, or other light-activated ion channel nucleic acid or polypeptide that is present in a vector, in a heterologous cell, tissue, or organism, etc., is still considered to be an isolated sequence. As used herein the term "host" used in reference to a membrane or cell in which a light-activated ion channel of the invention is expressed, means a membrane or cell that is not a cell or membrane in which the light-activated ion channel is expressed in nature. Thus a host membrane, cell, tissue, or organism for a light-activated ion channel molecule of the invention (such as a light-activated ion channel polypeptide or its encoding nucleic acid), as used herein is a membrane, cell, tissue, or organism in which the light-activated ion channel molecule of

the invention does not naturally occur and in which the light-activated ion channel is not naturally expressed. Examples of a host membrane, cell, tissue, or organism include, but are not limited to mammalian (including but not limited to non-human primate, human, etc.), insect, and avian membranes, cells, and tissues; as well as organisms such as mammals, insects, and birds. The term "heterologous" as used herein, means a membrane, cell, tissue, or organism that is not the native cell, tissue, or organism, and a light-activated ion channel polypeptide of the invention or its encoding nucleic acid may be present in a heterologous membrane, cell, tissue, or organism. The terms, "protein", "polypeptides", and "peptides" are used interchangeably herein.

Light-activated Ion Channel sequences including modified and derived sequences

[0046] A light-activated ion channel of the invention may comprise a wild-type polypeptide sequence or may be a modified polypeptide sequence. As used herein the term "modified" or "modification" in reference to a nucleic acid or polypeptide sequence refers to a change of one, two, three, four, five, six, or more amino acids in the sequence as compared to the wild-type or other sequence from which it was derived. For example, a modified polypeptide sequence may be identical to a wild-type polypeptide sequence except that it has one, two, three, four, five, or more amino acid substitutions, deletions, insertions, or combinations thereof. In some embodiments of the invention a modified sequence may include one, two, three, four, or more amino acid substitutions in a wild-type light-activated ion channel polypeptide sequence, or in any other light-activated ion channel polypeptide sequence of the invention.

[0047] The invention, in some aspects also includes light-activated ion channel polypeptides having one or more substitutions or other modifications from those described herein. For example, sequences of light-activated ion channel polypeptides provided herein can be modified with one or more substitutions, deletions, insertions, or other modifications and such derivative light-activated ion channels can be tested using methods described herein for characteristics including, but not limited to: expression, cell localization, activation and depolarization in response to contact with light using methods disclosed herein. Exemplary modifications include, but are not limited to conservative amino acid substitutions, which will produce molecules having functional characteristics similar to those of the molecule from which such modifications are made. Conservative amino acid substitutions are substitutions that do not result in a significant change in the activity or tertiary structure of a selected polypeptide or protein. Such substitutions typically involve replacing a selected amino acid residue with a different residue having similar physico-chemical properties. For example, substitution of Glu for Asp is considered a conservative substitution because both are similarly-sized negatively-charged amino acids. Groupings of amino acids by physico-chemical properties are known to those of skill in the art. The following groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Light-activated ion channels that include modifications, including but not limited to one, two, three, four, or more conservative amino acid substitutions can be identified and tested for characteristics including, but not limited to: expression, cell localization, activation and depolarization and depolarization-effects in response to contact with light using methods disclosed herein. As described elsewhere herein, in some polypeptide regions such as the transmembrane region of a light-activated ion channel of the invention, may include modifications that result in less than 100%, 95%, 90%, 85%, 80%, 75% identity with the sequence from which its derived, yet may have at least 95%, 96%, 97%, 98%, 99%, or 100% identity in its non-transmembrane regions of the polypeptide.

[0048] Sequence identity can be determined using standard techniques known in the art.

[0049] Light -activated ion channel polypeptides of the invention may be shorter or longer than the light-activated ion channel polypeptide sequences set forth herein. Thus, a light-activated ion channel polypeptide may be a full-length polypeptide or functional fragment thereof. In addition, nucleic acids of the invention may be used to obtain additional coding regions, and thus additional polypeptide sequences, using techniques known in the art.

[0050] In some aspects of the invention, substantially similar light-activated ion channel polypeptide sequences may have at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or 100% identity to light-activated ion channel polypeptide sequence ChR90. Art-known alignment methods and tools can be used to align substantially similar sequences permitting positional identification of amino acids that may be modified as described herein to prepare a light-activated ion channel of the invention. Standard sequence analysis tools and computer programs, such as those used for alignment, etc. can be used to identify light-activated ion channels of the invention that share one or more functional properties with a light-activated ion channel described herein.

[0051] Sequence modifications can be in one or more of three classes: substitutions, insertions, or deletions. These modified sequences, (which may also be referred to as variants, or derivatives) ordinarily are prepared by site specific mutagenesis of nucleic acids in the DNA encoding a light-activated ion channel polypeptide, using cassette or PCR mutagenesis or other techniques known in the art, to produce DNA encoding the modified light-activated ion channel, and thereafter expressing the DNA in recombinant cell culture. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the light-activated ion channels of the invention. Modified light-activated ion channels generally exhibit the same qualitative biological activity as the naturally occurring light-activated ion channel (e.g., wild-type), although variants can also be selected that have modified characteristics.

[0052] A site or region for introducing an amino acid sequence modification may be predetermined, and the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed modified light-activated ion channel screened for the

optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis.

[0053] Amino acid substitutions are typically of single residues; and insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions may range from about 1 to about 20 residues, although in some cases deletions may be much larger.

[0054] Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final modified light-activated ion channel of the invention. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances.

[0055] Variants of light-activated ion channels set forth herein, may exhibit the same qualitative light-activated ion channel activity as ChR90, but may show some altered characteristics such as altered photocurrent, stability, speed, compatibility, and toxicity, or a combination thereof. For example, the polypeptide can be modified such that it has an increased photocurrent and/or has less toxicity than another light-activated ion channel polypeptide.

[0056] A modified (or derived) light-activated ion channel polypeptide of the invention can incorporate unnatural amino acids as well as natural amino acids. An unnatural amino acid can be included in a light-activated ion channel of the invention to enhance a characteristic such as photocurrent, stability, speed, compatibility, or to lower toxicity, etc.

[0057] According to principles of this invention, the performance of light-activated ion channel molecules or classes of molecules can be tuned for optimal use, including in the context of their use in conjunction with other molecules or optical apparatus. For example, in order to achieve optimal contrast for multiple-color stimulation, one may desire to either improve or decrease the performance of one molecule with respect to one another, by the appendage of trafficking enhancing sequences or creation of genetic variants by site-directed mutagenesis, directed evolution, gene shuffling, or altering codon usage. Light-activated ion channel molecules or classes of molecules may have inherently varying spectral sensitivity. This may be used to advantage *in vivo* (where scattering and absorption will vary with respect to wavelength, coherence, and polarization), by tuning the linearity or non-linearity of response to optical illumination with respect to time, power, and illumination history.

[0058] In some embodiments, the invention includes the use of targeted site-directed mutagenesis at specific amino acid residues of *Stigeoclonium helveticum* channelrhodopsins. Specific locations for single mutations can be identified and alone, or in combination with two or more additional mutations can be placed into a channelrhodopsin sequence and tested with respect to their activation and photocurrent amplitude. Thus, sequences of light-activated ion channels of the invention, and/or similar channelrhodopsin sequences can be modified and the resulting polypeptides tested using methods disclosed herein.

[0059] Another aspect of the invention provides nucleic acid sequences that code for a light-activated ion channel of the invention. It would be understood by a person of skill in the art that light-activated ion channel polypeptides of the present invention can be coded for by various nucleic acids. Each amino acid in the protein is represented by one or more sets of 3 nucleic acids (codons). Because many amino acids are represented by more than one codon, there is not a unique nucleic acid sequence that codes for a given protein. It is well understood by those of skill in the art how to make a nucleic acid that can code for light-activated ion channel polypeptides of the invention by knowing the amino acid sequence of the protein. A nucleic acid sequence that codes for a polypeptide or protein is the "gene" of that polypeptide or protein. A gene can be RNA, DNA, or other nucleic acid that will code for the polypeptide or protein.

[0060] It is understood in the art that the codon systems in different organisms can be slightly different, and that therefore where the expression of a given protein from a given organism is desired, the nucleic acid sequence can be modified for expression within that organism. Thus, in some embodiments, a light-activated ion channel polypeptide of the invention is encoded by a mammalian-codon-optimized nucleic acid sequence, which may in some embodiments be a human-codon optimized nucleic acid sequence. An aspect of the invention provides a nucleic acid sequence that codes for a light-activated ion channel that is optimized for expression with a mammalian cell. In some embodiments of the invention, a nucleic acid that encodes a light-activated ion channel of the invention includes a nucleic acid sequence optimized for expression in a human cell.

Delivery of Light-activated Ion Channels

[0061] Delivery of a light-activated ion channel polypeptide to a cell and/or expression of a light-activated ion channel in a cell can be done using art-known delivery means.

[0062] A light-activated ion channel polypeptide of the invention may be included in a fusion protein. It is well known in the art how to prepare and utilize fusion proteins that comprise a polypeptide sequence. In certain embodiments of the invention, a fusion protein can be used to deliver a light-activated ion channel to a cell and can also in some embodiments be used to target a light-activated ion channel of the invention to specific cells or to specific cells, tissues, or regions in a subject. Targeting and suitable targeting sequences for delivery to a desired cell, tissue or region can be performed using art-known procedures.

[0063] A light-activated ion channel polypeptide of the invention may be non-toxic, or substantially non-toxic, in cells in which it is expressed. In the absence of light, a light-activated ion channel of the invention does not significantly alter cell health or ongoing electrical activity in the cell in which it is expressed.

[0064] A light-activated ion channel of the invention may be genetically introduced into a

cellular membrane, and reagents and methods are provided for genetically targeted expression of the light-activated ion channel polypeptide (ChR90 or a derivative thereof). Genetic targeting can be used to deliver light-activated ion channel polypeptides to specific cell types, to specific cell subtypes, to specific spatial regions within an organism, and to sub-cellular regions within a cell. Genetic targeting also relates to the control of the amount of light-activated ion channel polypeptide expressed, and the timing of the expression.

[0065] A reagent can be provided for genetically targeted expression of a light-activated ion channel polypeptide, wherein the reagent comprises a vector that contains the gene for the light-activated ion channel polypeptide.

[0066] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting between different genetic environments another nucleic acid to which it has been operatively linked. The term "vector" also refers to a virus or organism that is capable of transporting the nucleic acid molecule. One type of vector is an episome, i.e., a nucleic acid molecule capable of extra-chromosomal replication. Some useful vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". Other useful vectors, include, but are not limited to viruses such as lentiviruses, retroviruses, adenoviruses, and phages. Vectors useful the invention can genetically insert light-activated ion channel polypeptides into dividing and non-dividing cells and can insert light-activated ion channel polypeptides to cells that are *in vivo*, *in vitro*, or *ex vivo* cells.

[0067] Vectors useful in the invention may include additional sequences including, but not limited to one or more signal sequences and/or promoter sequences, or a combination thereof. Expression vectors and methods of their use are well known in the art. Non-limiting examples of suitable expression vectors and methods for their use are provided herein.

[0068] In certain embodiments of the invention, a vector may be a lentivirus comprising the gene for a light-activated ion channel of the invention, based on ChR90 or a derivative or variant thereof. A lentivirus is a non-limiting example of a vector that may be used to create stable cell line. The term "cell line" as used herein is an established cell culture that will continue to proliferate given the appropriate medium.

[0069] Promoters that may be used in methods and vectors of the invention include, but are not limited to, cell-specific promoters or general promoters. Methods for selecting and using cell-specific promoters and general promoters are well known in the art. A non-limiting example of a general purpose promoter that allows expression of a light-activated ion channel polypeptide in a wide variety of cell types - thus a promoter for a gene that is widely expressed in a variety of cell types, for example a "housekeeping gene" can be used to express a light-activated ion channel polypeptide in a variety of cell types. Non-limiting examples of general promoters are provided elsewhere herein and suitable alternative promoters are well known in the art.

[0070] In certain embodiments of the invention, a promoter may be an inducible promoter, examples of which include, but are not limited to tetracycline-on or tetracycline-off, or tamoxifen-inducible Cre-ER.

Methods of Use of Light Activated Ion Channels of the Invention

[0071] Light activated ion channels of the invention are well suited for targeting cells and specifically altering voltage-associated cell activities. Light-activated ion channels of the invention can be utilized to introduce cations into cells, thus activating endogenous signaling pathways (such as calcium dependent signaling), and then drugs are applied that modulate the response of the cell (using a calcium or voltage-sensitive dye). This allows new kinds of drug screening using just light to activate the channels of interest, and using just light to read out the effects of a drug on the channels of interest.

[0072] Chrimson is far-red-activatable, and thus allows excitation of cells with a color of light heretofore not used in biotechnology for excitation of cells. By using for example, Chrimson and Chronos together, excitation of two different populations of cells in the same tissue or in the same culture dish becomes possible. This simultaneous, two-color excitation is particularly promising for complex tissues such as the brain.

[0073] The performance of the above said molecules or classes of molecules can be tuned for optimal use, particularly in context of their use in conjunction with other molecules or optical apparatus. Such tuning can be done using standard methods known in the art. For example, in order to achieve optimal contrast for multiple-color stimulation, one may desire to either improve or decrease the performance of one molecule with respect to one another, by the appendage of trafficking enhancing sequences or creation of genetic variants by site-directed mutagenesis, directed evolution, gene shuffling, or altering codon usage. Molecules or classes of molecules may have inherently varying spectral sensitivity that may be functionally advantageous *in vivo* (where scattering and absorption will vary with respect to wavelength, coherence, and polarization), by tuning the linearity or non-linearity of response to optical illumination with respect to time, power, and illumination history.

[0074] Cations may be introduced into cells, thus activating endogenous signaling pathways (such as calcium dependent signaling), and drugs may be applied that modulate the response of the cell (using a calcium or voltage-sensitive dye). This enables new kinds of drug screening using just light to activate the channels of interest, and using just light to read out the effects of a drug on the channels of interest.

[0075] The light-activated channel may be used to decrease the pH of the cell. Such a technique may be used to treat alkalosis.

[0076] Light-activated proton pumps may be used for the coupled effect of hyperpolarization

and intracellular alkalization. For example, both phenomena can induce spontaneous spiking in neurons by triggering hyperpolarization-induced cation currents or pH-dependent hyper-excitability.

[0077] It is possible to generate sub-cellular voltage or pH gradients, particularly at synapses and in synaptic vesicles to alter synaptic transmission, and mitochondria to improve ATP synthesis.

[0078] Far-red (660nm) light may be used to perform non-invasive transcranial and/or transdural stimulation to modulate neural circuits.

[0079] Various compositions of matter have now been reduced to practice, for example: plasmids encoding for the above genes have been prepared; lentiviruses carrying payloads encoding for the above genes have been prepared; adeno-associated viruses carrying payloads encoding for the above genes have been prepared; cells expressing the above genes have been prepared; and animals expressing those genes have been prepared. (See for example: US Patent Publication 20110165681).

[0080] Working operation of a prototype of this invention was demonstrated by genetically expressing light-activated ion channel molecules of the invention in excitable cells, illuminating the cells with suitable wavelengths of light, and demonstrating rapid depolarization of the cells in response to the light, as well as rapid release from depolarization upon cessation of light. Depending on the particular implementation, the invention allows light control of cellular functions *in vivo*, *ex vivo*, and *in vitro*.

[0081] Channelrhodopsins of the invention and derivatives thereof can be used in mammalian cells without need for any kind of chemical supplement, and in normal cellular environmental conditions and ionic concentrations. For example, genes encoding channelrhodopsins of *Stigeoclonium* have been used. These sequences in humanized or mouse-optimized form allow depolarization at wavelengths described herein.

[0082] As used herein, the term "ion channel" means a transmembrane polypeptide that forms a pore, which when activated opens, permitting ion conductance through the pore across the membrane. Many ion channels do not express well in a cell and/or their expression may be toxic to the cell and reduce cell health. Thus it was necessary to prepare and screen numerous channelrhodopsin light-activated ion channel polypeptides to identify light-activated ion channels of the invention that can be expressed in cells without significantly reducing cell health and viability.

[0083] Light-activated ion channels of the invention have been found to be suitable for expression and use in mammalian cells without need for any kind of chemical supplement, and in normal cellular environmental conditions and ionic concentrations. Light-activated ion channels of the invention have been found to differ from previously identified channels, in that the Chronos light-activated ion channels activate at wavelengths of light ranging from 365 nm

to 630 nm, with an optimal activation from light ranging from 430 nm to 550 nm, and a peak optimal activation at a wavelength of 500 nm.

Cells and Subjects

[0084] A cell used in the invention may be an excitable cell or a non-excitable cell. A cell in which a light-activated ion channel of the invention may be expressed and which may be used in the invention includes prokaryotic and eukaryotic cells. Useful cells include but are not limited to mammalian cells. Examples of cells in which a light-activated ion channel of the invention may be expressed are excitable cells, which include cells able to produce and respond to electrical signals. Examples of excitable cell types include, but are not limited to neurons, muscles, cardiac cells, and secretory cells (such as pancreatic cells, adrenal medulla cells, pituitary cells, etc.).

[0085] Non-limiting examples of cells that may be used in the invention include: neuronal cells, nervous system cells, cardiac cells, circulatory system cells, visual system cells, auditory system cells, secretory cells, endocrine cells, or muscle cells. In some embodiments, a cell used in conjunction with the invention may be a healthy normal cell, which is not known to have a disease, disorder or abnormal condition. In some embodiments, a cell used in conjunction with the invention may be an abnormal cell, for example, a cell that has been diagnosed as having a disorder, disease, or condition, including, but not limited to a degenerative cell, a neurological disease-bearing cell, a cell model of a disease or condition, an injured cell, etc. In some embodiments of the invention, a cell may be a control cell.

[0086] Light-activated ion channels of the invention may be expressed in cells from culture, cells in solution, cells obtained from subjects, and/or cells in a subject (*in vivo* cells). Light-activated ion channels may be expressed and activated in cultured cells, cultured tissues (e.g., brain slice preparations, etc.), and in living subjects, etc. As used herein, the term "subject" may refer to a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat, rodent, fly or any other vertebrate or invertebrate organism.

Controls and candidate compound testing

[0087] Light-activated ion channels of the invention and methods using light-activated ion channels of the invention can be utilized to assess changes in cells, tissues, and subjects in which they are expressed. Light-activated ion channels of the invention can be used to identify effects of candidate compounds on cells, tissues, and subjects. Results of testing a light-activated ion channel of the invention can be advantageously compared to a control. In some embodiments of the invention one or more light-activated ion channels of the invention (ChR90, or a derivative thereof) may be expressed in a cell population and used to test the effect of candidate compounds on the cells.

[0088] As used herein a control may be a predetermined value, which can take a variety of forms. It can be a single cut-off value, such as a median or mean. It can be established based upon comparative groups, such as cells or tissues that include the light-activated ion channel and are contacted with light, but are not contacted with the candidate compound and the same type of cells or tissues that under the same testing condition are contacted with the candidate compound. Another example of comparative groups may include cells or tissues that have a disorder or condition and groups without the disorder or condition. Another comparative group may be cells from a group with a family history of a disease or condition and cells from a group without such a family history. A predetermined value can be arranged, for example, where a tested population is divided equally (or unequally) into groups based on results of testing. Those skilled in the art are able to select appropriate control groups and values for use in comparative methods.

[0089] As a non-limiting example of use of a light-activated ion channel to identify a candidate therapeutic agent or compound, a light-activated ion channel of the invention may be expressed in an excitable cell in culture or in a subject and the excitable cell may be contacted with a light that activates the light-activated ion channel and with a candidate therapeutic compound. In one embodiment, a test cell that includes a light-activated ion channel of the invention can be contacted with a light that depolarizes the cell and also contacted with a candidate compound. The cell, tissue, and/or subject that include the cell can be monitored for the presence or absence of a change that occurs in the test conditions versus the control conditions. For example, in a cell, a change may be a change in the depolarization or in a depolarization-mediated cell characteristic in the test cell versus a control cell, and a change in depolarization or the depolarization-mediated cell characteristic in the test cell compared to the control may indicate that the candidate compound has an effect on the test cell or tissue that includes the cell. In some embodiments, a depolarization-mediated cell characteristic may be an action potential, pH change in a cell, release of a neurotransmitter, etc. and may in some embodiments include a downstream effect on one or more additional cells, which occurs due to the depolarization of the cell that includes the light-activated ion channel. Art-known methods can be used to assess depolarization and depolarization-mediated cell characteristics and changes to the depolarization or depolarization-mediated cell characteristics upon activation of a light-activated ion channel of the invention, with or without additional contact with a candidate compound.

[0090] Candidate-compound identification methods that are performed in a subject may include expressing a light-activated ion channel in a subject, contacting the subject with a light under suitable conditions to activate the light-activated ion channel and depolarize the cell, and administering to the subject a candidate compound. The subject is then monitored to determine whether any change occurs that differs from a control effect in a subject. Thus, for example, a cell in culture can be contacted with a light appropriate to activate a light-activated ion channel of the invention in the presence of a candidate compound. A result of such contact with the candidate compound can be measured and compared to a control value as a determination of the presence or absence of an effect of the candidate compound.

[0091] Methods of identifying effects of candidate compounds using light-activated ion channels of the invention may also include additional steps and assays to further characterizing an identified change in the cell, tissue, or subject when the cell is contacted with the candidate compound. In some embodiments, testing in a cell, tissue, or subject can also include one or more cells that has a light-activated ion channel of the invention, and that also has one, two, three, or more additional different light-activated ion channels, wherein at least one, two, three, four, or more of the additional light-activated ion channels is activated by contact with light having a different wavelength than used to activate the Chronos or derivative thereof, light-activated ion channel of the invention.

[0092] In a non-limiting example of a candidate drug identification method which is described but not claimed, cells that include a light-activated ion channel of the invention are depolarized, thus triggering release of a neurotransmitter from the cell, and then drugs are applied that modulate the response of the cell to depolarization (determined for example using patch clamping methods or other suitable art-known means). Such methods enable new kinds of drug screening using just light to activate the channels of interest, and using just light to read out the effects of a drug on the channels and channel-containing cells of interest.

[0093] In some embodiments, light-activated ion channel polypeptides of the invention can be used in test systems and assays for assessing membrane protein trafficking and physiological function in heterologously expressed systems and the use of use of light-activated channels to depolarize a cell.

[0094] In some aspects which are described but not claimed, two-color assays can be performed. For example, Chronos (for blue light activation) and Chrimson (for red light activation) can be expressed in separate sets cells that represent non-overlapping neuronal populations. Following expression, the cell population can be exposed to light and the wavelength and timing and "dose" of light can be optimized. As used herein the term "dose" in reference to light, may take into account of wavelength, pulse length, intensity, of the light with which a light-activated ion channel of the invention is contacted.

[0095] A non-limiting example of a procedure for optimizing the use of two-color activated populations of cells, which is described but not claimed, is provided as follows. A population that has Chronos and Chrimson expressed in different sub-populations is contacted with blue light having a wavelength between 400 nm and 500 nm, or between 450 nm to 500 nm, and having a pulse width of between 1 and 5 ms for activation. A pulse width of 5 ms provides for minimum sub-threshold crosstalk in the blue light, which is defined as <15 mV, <10 mV, and optimally as <5 mV. The maximum blue light power that can be used is determined using by patch clamping Chrimson expressing cells, illuminating with blue light and measuring voltage deflection. Optimally using blue light power such that maximum voltage deflection is <10mV, which in some embodiments may be 0.4 to 0.6mW/mm². The optimal blue light power that can be used to drive Chronos is determined using the same conditions as above, except using lower light power, such as 50uW/mm² to 0.4mW/mm², which in some embodiments may be

0.2mW/mm². Power depends on expression system and cell type used to prepare the population. The population can be contacted with red light having a wavelength between 600 nm and 700 nm, or 620 nm and 640nm, and with a pulse width of between 1 and 5 ms for activation, which in some embodiments may be optimized at 5ms. In certain embodiments of the invention, the optimal light power to drive Chrimson in the red may be determined by ramping light powers from for example, 0.1 mW/mm² to 100 mW/mm², or from 0.5mW/mm² to 10mW/mm². The method may be optimized such that a minimum red light power is used to achieve 100% spiking for Chrimson.

[0096] It will be understood that other sets of 2, 3, 4, or more light-activated ion channels may be expressed in separate subpopulations of a population of cells and then exposed to doses of light in a manner as described here to optimize their use in assays and treatments. A non-limiting example of a process to prepare and use a multi-light activated population of cells is as follows. A first light-activated ion channel is expressed in a first subpopulation of a population of cells; a second light-activated ion channel is expressed in a second subpopulation of the population of cells, wherein the first and second subpopulations are non-overlapping subpopulations, and the first light-activated ion channel and second light activated ion channel are have ranges of activating light wavelengths that do not entirely overlap. The population of cells is contacted with a plurality of first light test doses comprising combinations of wavelength, pulse width, and power that activate the first subpopulation, and the transmembrane voltage deflection is measured in a cell of the second subpopulation of cells contacted with the first light test doses. The first light test dose that includes a maximum light power that activates the light activated ion channel in first subpopulation of cells and results in a minimum sub-threshold transmembrane voltage deflection in the second subpopulation of cells is determined. The population of cells is then contacted with a plurality of first light test doses comprising a lower power than the maximum first light power that was determined, and a first light test doses that activate the first light activated ion channel (at the lower powers) are determined. The population of cells is then contacted with a plurality of second light test doses that include combinations of light wavelength, pulse width, and power that activate the second subpopulation, and a second light test dose comprising a second light power that activates the second subpopulation of cells is determined. Assays can be performed using such a population of cells, that includes contacting the population of cells with the first light test dose and the second light test dose determined using the steps above. The above-described process of optimizing light dose parameters for multi-light activated ion channels can be used to design and implement assays that include light-activated ion channels of the invention, as well as other light-activated ion channels that are known in the art.

Methods of Treating

[0097] The claimed invention provides a light-activated ion channel polypeptide, a nucleic acid, or a vector for use in a method of treating a disorder in a subject, as defined in claim 10. The claimed invention further provides a light-activated ion channel polypeptide for use in a method

of medical treatment of a subject, as defined in claim 11. Such treatment methods may include administering to a subject in need of such treatment, a therapeutically effective amount of a light-activated ion channel of the invention to treat the disorder. It will be understood that a treatment may be a prophylactic treatment or may be a treatment administered following the diagnosis of a disease or condition. A treatment of the invention may reduce or eliminate a symptom or characteristic of a disorder, disease, or condition or may eliminate the disorder, disease, or condition itself. It will be understood that a treatment of the invention may reduce or eliminate progression of a disease, disorder or condition and may in some instances result in the regression of the disease, disorder, or condition. A treatment need not entirely eliminate the disease, disorder, or condition to be effective. In some embodiments of the invention one or more light-activated ion channels of the invention ChR90 or a derivative thereof may be expressed in a cell population and used to treat a disorder or condition.

[0098] Administration of a light-activated ion channel of the invention may include administration of a pharmaceutical composition that includes a cell, wherein the cell expresses the light-activated ion channel. Administration of a light-activated ion channel of the invention may include administration of a pharmaceutical composition that includes a vector, wherein the vector comprises a nucleic acid sequence encoding the light-activated ion channel and the administration of the vector results in expression of the light-activated ion channel in a cell in the subject.

[0099] An effective amount of a light-activated ion channel is an amount that increases the level of the light-activated ion channel in a cell, tissue or subject to a level that is beneficial for the subject. An effective amount may also be determined by assessing physiological effects of administration on a cell or subject, such as a decrease in symptoms following administration. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response to a treatment. The amount of a treatment may be varied for example by increasing or decreasing the amount of the light-activated ion channel administered, by changing the therapeutic composition in which the light-activated ion channel is administered, by changing the route of administration, by changing the dosage timing, by changing the activation amounts and parameters of a light-activated ion channel of the invention, and so on. The effective amount will vary with the particular condition being treated, the age and physical condition of the subject being treated; the severity of the condition, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration, and the like factors within the knowledge and expertise of the health practitioner. For example, an effective amount may depend upon the location and number of cells in the subject in which the light-activated ion channel is to be expressed. An effective amount may also depend on the location of the tissue to be treated.

[0100] Effective amounts will also depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be

addressed with no more than routine experimentation. It is generally preferred that a maximum dose of a composition to increase the level of a light-activated ion channel, and/or to alter the length or timing of activation of a light-activated ion channel in a subject (alone or in combination with other therapeutic agents) be used, that is, the highest safe dose or amount according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

[0101] A light-activated ion channel of the invention (ChR90 or a derivative thereof) may be administered using art-known methods. In some embodiments a nucleic acid that encodes a light-activated ion channel polypeptide of the invention is administered to a subject and in certain embodiments a light-activated ion channel polypeptide is administered to a subject. The manner and dosage administered may be adjusted by the individual physician or veterinarian, particularly in the event of any complication. The absolute amount administered will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual subject parameters including age, physical condition, size, weight, and the stage of the disease or condition. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.

[0102] Pharmaceutical compositions that deliver light-activated ion channels of the invention may be administered alone, in combination with each other, and/or in combination with other drug therapies, or other treatment regimens that are administered to subjects. A pharmaceutical composition used preferably contains an effective amount of a therapeutic compound that will increase the level of a light-activated ion channel polypeptide to a level that produces the desired response in a unit of weight or volume suitable for administration to a subject.

[0103] The dose of a pharmaceutical composition that is administered to a subject to increase the level of light-activated ion channel in cells of the subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. The amount and timing of activation of a light-activated ion channel of the invention (e.g., light wavelength, length of light contact, etc.) that has been administered to a subject can also be adjusted based on efficacy of the treatment in a particular subject. Parameters for illumination and activation of light-activated ion channels that have been administered to a subject can be determined using art-known methods and without requiring undue experimentation.

[0104] Various modes of administration will be known to one of ordinary skill in the art that can be used to effectively deliver a pharmaceutical composition to increase the level of a light-activated ion channel of the invention in a desired cell, tissue or body region of a subject.

Methods for administering such a composition or other pharmaceutical compound of the invention may be topical, intravenous, oral, intracavity, intrathecal, intrasynovial, buccal, sublingual, intranasal, transdermal, intravitreal, subcutaneous, intramuscular and intradermal administration. The invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., Remington's Pharmaceutical Sciences, 18th edition, 1990) provide modes of administration and formulations for delivery of various pharmaceutical preparations and formulations in pharmaceutical carriers. Other protocols which are useful for the administration of a therapeutic compound of the invention will be known to one of ordinary skill in the art, in which the dose amount, schedule of administration, sites of administration, mode of administration (e.g., intra-organ) and the like vary from those presented herein.

[0105] Administration of a cell or vector to increase light-activated ion channel levels in a mammal other than a human; and administration and use of light-activated ion channels of the invention, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above. It will be understood by one of ordinary skill in the art that this invention is applicable to both human and animals. Thus this invention is intended to be used in husbandry and veterinary medicine as well as in human therapeutics.

[0106] A light-activated ion channel of the invention may be applied to cells including but not limited to a neuronal cell, a nervous system cell, a neuron, a cardiac cell, a circulatory system cell, a visual system cell, an auditory system cell, a muscle cell, or an endocrine cell, etc. Disorders and conditions that may be treated include injury, brain damage, degenerative neurological conditions (e.g., Parkinson's disease, Alzheimer's disease), seizure, vision loss, hearing loss, etc.

Disorders, Diseases and Conditions

[0107] Light-activated ion channels of the invention may be used to target cells and membranes, and to alter voltage-associated cell activities. A light-activated ion channel of the invention may be used to decrease the pH of a cell in which it is expressed. Such a technique may be used to treat alkalosis.

[0108] Described but not claimed are methods of using light-activated proton pumps in conjunction with the use of light-activated ion channels of the invention for the coupled effect of hyperpolarization and intracellular alkalinization. For example, both phenomena can induce spontaneous spiking in neurons by triggering hyperpolarization-induced cation currents or pH-dependent hyper-excitability.

[0109] Described but not claimed is expressing light-activated ion channels of the invention into cell membranes and then activating the light-activated ion channels and generate sub-cellular voltage or pH gradients, particularly at synapses and in synaptic vesicles to alter synaptic transmission, and mitochondria to improve ATP synthesis.

[0110] In some embodiments, light-activated ion channels of the invention may be used for the treatment of visual system disorders, for example to treat vision reduction or loss. A light-activated ion channel of the invention may be administered to a subject who has a vision reduction or loss and the expressed light-activated ion channel can function as light-sensitive cells in the visual system, thereby permitting a gain of visual function in the subject.

[0111] Described but not claimed is preparing nucleic acid sequences and polynucleotide sequences; expressing in cells and membranes polypeptides encoded by the prepared nucleic acid and polynucleotide sequences; illuminating the cells and/or membranes with suitable light, and demonstrating rapid depolarization of the cells and/or a change in conductance across the membrane in response to light, as well as rapid release from depolarization upon cessation of light. The ability to controllably alter voltage across membranes and cell depolarization with light has been demonstrated. The present invention enables light-control of cellular functions *in vivo*, *ex vivo*, and *in vitro*, and the light activated ion channels of the invention and their use, have broad-ranging applications for drug screening, treatments, and research applications, some of which are described herein.

[0112] The ability to optically perturb, modify, or control cellular function offers many advantages over physical manipulation mechanisms. These advantages comprise speed, non-invasiveness, and the ability to easily span vast spatial scales from the nanoscale to macroscale.

[0113] The reagents used (and the class of molecules that they represent), allow, at least: currents activated by light wavelengths not useful in previous light-activated ion channels, light activated ion channels that when activated, permit effectively zero calcium conductance, and different spectra from older molecules (opening up multi-color control of cells).

Examples

Example 1

[0114] Studies were performed to prepare sequences and to express light-activated ion channels in cells, tissues, and subjects. Identifications and amino acid sequences of some of the light-activated ion channels in the examples are ChR88 (SEQ ID NO:2); ChR90 (SEQ ID NO:7); ChR87 (SEQ ID NO:11); ChR62 (SEQ ID NO:14), ChR93 (SEQ ID NO: 16) and ChR2 (SEQ ID NO:19), ChR88 K176R (SEQ ID NO:5). Non-limiting exemplary methods are set forth Example 1. General methods also applicable to light-activated channel molecules and methods for their use are disclosed in publications such as US Published Application No. 2010/0234273, US Published Application No. 20110165681, Chow BY, et. al. Methods Enzymol. 2011;497:425-43; Chow, BY, et al. Nature 2010 Jan 7;463(7277):98-102.

[0115] Studies were performed to prepare sequences and to express light-activated ion channels in cells, tissues, and subjects. Non-limiting exemplary methods are set forth below.

(a) In utero electroporation

[0116] All procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Massachusetts Institute of Technology Committee on Animal Care. C57BL/6J E16-timed pregnant mice were used for electroporation. Surgery was done under ketamine-xylazine anesthesia and buprenorphine analgesia, DNA solution containing plasmids of interest were injected into lateral ventricle of each embryo using a pulled capillary tube. Five square pulses (50ms width, 1Hz, 35V) were applied using tweezer electrode for electroporation.

(b) Slice preparation

[0117] P20-P30 mice were used for slice preparation. In younger animals it was difficult to elicit synaptic responses by photostimulating callosal axons. Mice were anesthetized with isofluorane and transcardially perfused with artificial cerebrospinal fluid (ACSF). The brain was removed and placed in an ice-cold cutting solution containing 110 mM choline chloride, 25 mM NaHCO₃, 25 mM D-glucose, 11.6 mM sodium ascorbate, 7 mM MgCl₂, 3.1 mM sodium pyruvate, 2.5 mM KCl, 1.25 mM NaH₂PO₄ and 0.5 mM CaCl₂. 300-μm-thick coronal slices of the visual cortex were cut with a vibrating slicer and incubated in oxygenated ACSF for 45 min at 37°C before the recordings.

(c) Slice Electrophysiology

[0118] Recordings were performed at room temperature (22-24° C) under constant perfusion of oxygenated ACSF. Neurons were visualized using infrared differential interference optics and patched with borosilicate pipettes (resistance 4-6 MO). The intracellular solution contained 120 mM potassium gluconate, 5 mM NaCl, 2 mM MgCl₂, 0.1 mM CaCl₂, 10 mM HEPES, 1.1 mM EGTA, 4 mM magnesium ATP, 0.4 mM disodium GTP, (pH 7.25; 290 mOsm). Cells were recorded at a depth of 30-120 μm in the brain slice. Photostimulation was done using a blue LED (470 nm; Thorlabs, Newton, NJ) and a red LED (625nm with 632/22nm filter; Thorlabs).

(d) Neuron culture, transfection, infection, and imaging

[0119] All procedures involving animals were in accordance with the National Institutes of Health Guide for the care and use of laboratory animals and approved by the Massachusetts

Institute of Technology Animal Care and Use Committee. Swiss Webster or C57 mice [Taconic (Hudson, NY) or Jackson Labs (Bar Harbor, ME)] were used. For hippocampal cultures, hippocampal regions of postnatal day 0 or day 1 mice were isolated and digested with trypsin (1 mg/ml) for ~12 min, and then treated with Hanks solution supplemented with 10-20% fetal bovine serum and trypsin inhibitor (Sigma Aldrich, St Louis, MO). Tissue was then mechanically dissociated with Pasteur pipettes, and centrifuged at 1000 rpm at 4°C for 10 min. Dissociated neurons were plated at a density of approximately four hippocampi per 20 glass coverslips, coated with Matrigel (BD Biosciences, San Jose, CA). For cortical cultures, dissociated mouse cortical neurons (postnatal day 0 or 1) were prepared as previously described, and plated at a density of 100-200k per glass coverslip coated with Matrigel (BD Biosciences). Cultures were maintained in Neurobasal Medium supplemented with B27 (Invitrogen [Life Technologies, Grand Isle, NY]) and glutamine. Hippocampal and cortical cultures were used interchangeably; no differences in reagent performance were noted.

[0120] Neurons were transfected at 3-5 days in vitro using calcium phosphate (Invitrogen). GFP fluorescence was used to identify successfully transfected neurons. Alternatively, neurons were infected with 0.1-3 μ l of lentivirus or adeno-associated virus (AAV) per well at 3-5 days in vitro.

(e) HEK 293FT cell culture and transfection

[0121] HEK 293FT cells (Invitrogen) were maintained between 10-70% confluence in D10 medium (Cellgro [Mediatech/Corning, Manassas, VA]) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin/streptomycin (Cellgro), and 1% sodium pyruvate (Biowhittaker, Walkersville, MD). For recording, cells were plated at 5-20% confluence on glass coverslips coated with Matrigel (BD Biosciences). Adherent cells were transfected approximately 24 hours post-plating either with TransLT 293 lipofectamine transfection kits (Mirus Bio, LLC, Madison, WI) or with calcium phosphate transfection kits (Invitrogen), and recorded via whole-cell patch clamp between 36-72 hours post-transfection.

(f) In vitro whole cell patch clamp recording & optical stimulation

[0122] Whole cell patch clamp recordings were made using a Multiclamp 700B amplifier, a Digidata 1440 digitizer, and a PC running pClamp (Molecular Devices). Neurons were bathed in room temperature Tyrode containing 125 mM NaCl, 2 mM KCl, 3 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 30 mM glucose, 0.01 mM NBQX and 0.01 mM GABAzine. The Tyrode pH was adjusted to 7.3 with NaOH and the osmolarity was adjusted to 300 mOsm with sucrose. HEK cells were bathed in a Tyrode bath solution identical to that for neurons, but lacking GABAzine and NBQX. Borosilicate glass pipettes (Warner Instruments, Hamden, CT) with an outer diameter of 1.2 mm and a wall thickness of 0.255 mm were pulled to a resistance of 3-9 M Ω with a P-97 Flaming/Brown micropipette puller (Sutter Instruments, Novato, CA) and filled with

a solution containing 125 mM K-gluconate, 8 mM NaCl, 0.1 mM CaCl_2 , 0.6 mM MgCl_2 , 1 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, and 0.4 mM Na-GTP. The pipette solution pH was adjusted to 7.3 with KOH and the osmolarity was adjusted to 298 mOsm with sucrose. Access resistance was 5-30 M Ω , monitored throughout the voltage-clamp recording. Resting membrane potential was $\sim$ -60 mV for neurons and $\sim$ -30 mV for HEK 293FT cells in current-clamp recording.

[0123] Photocurrents were measured with 500 ms light pulses in neurons voltage-clamped at -60 mV, and in HEK 293FT cells voltage-clamped at -30 mV. Light-induced membrane hyperpolarizations were measured with 500 ms light pulses in cells current-clamped at their resting membrane potential. Light pulses for all wavelengths except 660 nm and action spectrum characterization experiments were delivered with a DG-4 optical switch with 300 W xenon lamp (Sutter Instruments), controlled via TTL pulses generated through a Digidata signal generator. Green light was delivered with a 575 ± 25 nm bandpass filter (Chroma) and a 575 ± 7.5 nm bandpass filter (Chroma Technology Group, Bellows Falls, VT). Action spectra were taken with a Till Photonics Polychrome V, 150 W Xenon lamp, 15 nm monochromator bandwidth.

[0124] Data was analyzed using Clampfit (Molecular Devices) and MATLAB (Mathworks, Inc.)

(g) Ion Conductance Recording

[0125] Whole-cell patch clamp recordings were performed in isolated HEK293FT cells to accurately measure parameters from single cells. All recordings were performed using an Axopatch 200B amplifier and Digidata 1440 digitizer (Molecular Devices) at room temperature. In order to allow isolated cell recording, cells were plated at a lower density of 15,000 cells per well in 24-well plates that contained round glass coverslips (0.15 mm thick, 25 mm in diameter, coated with 2 % Growth Factor Reduced Matrigel in DMEM for 1 h at 37 °C). For most recordings, Tyrode was used as the extracellular solution, and the intracellular solution consisted of (in mM) 125 K-Gluconate, 8 NaCl, 0.1 CaCl_2 , 0.6 MgCl_2 , 1 EGTA, 10 HEPES, 4 MgATP, 0.4 NaGTP, pH 7.3 (KOH adjusted), with 295-300 mOsm (sucrose adjusted). Extracellular and intracellular solutions used for testing ion permeability are listed in Table 1.

Table 1. Compositions of solutions used in ion permeability experiments

Solution	[Na] (mM)	[K] (mM)	[Ca] (mM)	[H] (mM)	pH	Other
Intracellular	0	140	0	$5.10\text{E}-05$	7.4	5 mM EGTA, 2 mM MgCl_2 , 10 mM HEPES
145 mM NaCl	145	5	1	$5.10\text{E}-05$	7.4	10 mM HEPES, 5 mM glucose, 2 mM MgCl_2
145 mM KCl	0	145	1	$5.10\text{E}-05$	7.4	10 mM HEPES, 5 mM glucose, 2 mM MgCl_2

Solution	[Na] (mM)	[K] (mM)	[Ca] (mM)	[H] (mM)	pH	Other
90 mM CaCl ₂	0	5	91	5.10E- 05	7.4	10 mM HEPES, 5 mM glucose, 2 mM MgCl ₂
5 mM NaCl	5	5	1	5.10E- 04	6.4	135 mM NMDG, 10 mM HEPES, 5 mM glucose, 2 mM MgCl ₂

[0126] Liquid junction potentials were measured using standard procedures to be 5.8 mV for the 90 mM CaCl₂ and 4.9 mV for the 5 mM NaCl extracellular solutions, which were corrected during recording; the others were < 1 mV in junction potential.

[0127] In all patch clamp recordings, a stringent cutoff of access resistance less than 25 MΩ and holding current less than ± 50 pA was applied in order to ensure accurate measurement. Typical membrane resistance was between 500 MΩ - 2 GΩ and pipette resistance was between 4 - 10 MΩ.

[0128] Photostimulation of patch clamped cells was conducted by a 470 nm LED (Thorlabs) at 10 mW/mm² unless otherwise stated. For most experiments, 1s illumination was delivered to measure transient and steady-state photocurrents.

(h) Plasmid construction and site directed mutagenesis.

[0129] Opsins were mammalian codon-optimized, and synthesized by Genscript (Genscript Corp., NJ). Opsins were fused in frame, without stop codons, ahead of GFP (using BamHI and AgeI) in a lentiviral vector containing the CaMKII promoter, enabling direct neuron transfection, HEK cell transfection (expression in HEK cells is enabled by a ubiquitous promoter upstream of the lentiviral cassette), and lentivirus production and transfection. Amino acid sequences of some opsins that were tested were as follows: ChR88 (SEQ ID NO:2); ChR90 (SEQ ID NO:7); ChR87 (SEQ ID NO:11); ChR62 (SEQ ID NO:14), ChR93 (SEQ ID NO: 16) and ChR2 (SEQ ID NO:19), ChR88 K176R (SEQ ID NO:5).

[0130] The 'ss' signal sequence from truncated MHC class I antigen corresponded to amino acid sequence (M)VPCTLLLLLAAALAPTQTRA (SEQ ID NO:21), DNA sequence gtcccggtgcacgctgctcctgctgttggcagccgccctggctccgactcagacgcgggcc (SEQ ID NO:20). The 'ER2' ER export sequence corresponded to amino acid sequence FCYENEV (SEQ ID NO:23), DNA sequence ttctgctacgagaatgaagt (SEQ ID NO:22). The 'KGC' signal sequence corresponded to amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:25), DNA sequence of KGC signal sequence : aaatccagaattacttctgaaggggagtagtatccctctggatcaaataagacatcaatgtt. (SEQ ID NO:24).

[0131] Point mutants for HEK cell testing were generated using the QuikChange kit [Stratagene, (Agilent Technologies, Santa Clara, CA)] on the opsin-GFP fusion gene inserted between BamHI and AgeI sites in a modified version of the pEGFP-N3 backbone [Invitrogen, (Life Technologies Corporation, Carlsbad, CA)]. All constructs were verified by sequencing.

(i) Lentivirus preparation

[0132] HEK293FT cells [Invitrogen, (Life Technologies Corporation, Carlsbad, CA)] were transfected with the lentiviral plasmid, the viral helper plasmid pΔ8.74, and the pseudotyping plasmid pMD2.G. The supernatant of transfected HEK cells containing virus was then collected 48 hours after transfection, purified, and then pelleted through ultracentrifugation. Lentivirus pellet was resuspended in phosphate buffered saline (PBS) and stored at -80°C until further usage *in vitro* or *in vivo*. The estimated final titer is approximately 10^9 infectious units/mL.

Example 2

[0133] Light-activated ion channels VChR1, ChR1, ChR2, ChR87, ChR90, and ChR88 were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 1 shows channelrhodopsin photocurrents measured in the cultured hippocampal neurons. Fig. 1A shows results using red light (660nm) peak photocurrent at 10 mW mm^{-2} for 1s illumination. ChR88 is the only red light sensitive channelrhodopsin with significant photocurrent at 660nm. Fig. 1B shows results using blue (4.23 mW mm^{-2}) or green (3.66 mW mm^{-2}) light peak photocurrent at equal photon flux for 5ms illumination. ChR87, ChR88, and ChR90 all have greater or comparable photocurrent than ChR2. Solid bar indicates blue light, horizontal striped bar indicates green light.

Example 3

[0134] HEK 293FT cells were transfected to express ChR2, ChR90, VChR1, ChR88, and ChR87 light-activated ion channels using methods of Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the transfected, cultured cells using methods described in Example 1. Figure 2 show action spectrum at equal photon dose at all wavelengths recorded in HEK293FT cells. ChR2 (470nm peak) and VChR1 (545nm peak) represent the existing channelrhodopsin color sensitivity range. ChR87 (515nm peak) and ChR90 (500nm peak) are blue green light sensitive channelrhodopsins. Whereas ChR88 (590nm peak) is the first red light sensitive natural channelrhodopsin.

Example 4

[0135] Light-activated ion channels ChR90 and ChR88 were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 3 shows optically-driven spikes in the cultured hippocampal neurons. Fig. 3A shows red-light-driven spike trains at low frequency for ChR88. Generally ChR88 could reliably drive spikes up to 5Hz. However at higher frequency such as 20Hz, ChR88 desensitizes and/or causes depolarization block. Fig. 3B shows green-light-driven spike trains at high frequency for ChR90. Due to ChR90 fast tau off and peak photocurrent recovery kinetics, it was able to drive temporally precise spikes at the highest frequency a neuron is capable of mediating.

Example 5

[0136] Light-activated ion channels ChR88, ChR2, ChR87, and ChR90 were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 4 illustrates the results and shows channelrhodopsin kinetics measured in the hippocampal neuron culture voltage clamped at -65mV. Fig. 4A shows single exponential channel turn-off kinetics based on 5 ms pulse. ChR90 had the fastest turn-off kinetics (3.5ms) observed across all natural channelrhodopsins. Fig. 4B showed peak photocurrent recovery ratio based on 1s illumination. ChR87 and ChR90 both had fast peak photocurrent recovery at around 70%. However ChR88 had slow recovery kinetics similar to ChR2.

Example 6

[0137] Light-activated ion channels Chrimson (ChR88) were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 5 shows Chrimson blue light crosstalk characterization in cultured neurons. Fig. 5A shows action spectrum of Chrimson and the blue light (470nm) wavelength used for illumination. Wavelength was chosen to minimize crosstalk. Fig. 5B shows representative traces from a single neuron at various illumination conditions. When the blue light power was doubled from 0.1 to 0.2 mW mm⁻² while the stimulation protocol was fixed as 5ms 5Hz, the voltage deflection was also doubled. However when the blue light power was fixed at 0.1 mW mm⁻² but the pulse duration was changed from 5ms to 1000ms, the crosstalk was changed from <5 mV to full spiking correspondingly. This means blue light crosstalk was a function of both light power and light

pulse duration (total photon count).

Example 7

[0138] Light-activated ion channels Chronos (ChR90) and ChR2 were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 6 illustrates Chronos and ChR2 blue light sensitivity in cultured hippocampal neurons. Fig. 6A is a spike irradiance curve for individual neurons. Fig. 6B shows lowest light power needed for single-cell 100% spike probability vs GFP fluorescence. Chronos (circles) was approximately 5 times more light sensitive than ChR2 (triangles) at a given (GFP) expression level. Fig. 6C shows example traces of Chronos spiking at various light powers. Fig. 6D illustrates that controls showed no significant electrical differences between ChR2 and Chronos expressing neurons.

Example 8

[0139] *In utero* electroporation and slice preparation methods as described in Example 1 were used to examine Chronos (ChR90) and Chrimson (ChR88) activation. Figure 7 illustrates the strategy used for slice characterization of Chronos and Chrimson. Fig. 7A shows illumination wavelength used for slice experiments. Fig. 7B provides micrographic images showing histology for Chronos and Chrimson GFP fusion construct singly expressed in layer 2/3 visual cortex in mice.

Example 9

[0140] *In utero* electroporation, slice preparation, and slice electrophysiology methods as described in Example 1 were used to characterize Chrimson (ChR88) and Chronos (ChR90) blue and red light sensitivity in slice preparations. Figure 8 illustrates results obtained using whole cell patch clamp methods. Fig. 8A shows that red light elicited 100% spiking in Chrimson expressing neurons but not Chronos expressing neurons between 1-6.5 mW mm⁻². Fig. 8B shows that blue light at 0.2-0.5 mW mm⁻² could elicit 100% spiking in Chronos expressing cells but not Chrimson expressing cells. However full spiking crosstalk in Chrimson expressing cells can occur at powers higher than 0.6 mW mm⁻². Fig. 8C shows blue light crosstalk voltage of Chrimson expressing neurons.

Example 10

[0141] *In utero* electroporation, slice preparation, and slice electrophysiology methods as described in Example 1 were used to characterize Chrimson (ChR88) and Chronos (ChR90). Figure 9 illustrates results with example traces of current-clamped opsin-expressing neurons in layer 2/3 slice blue light 0.1 mW mm^{-2} , red light 1 mW mm^{-2} expressing. No crosstalk was observed under red light for Chronos while minimal subthreshold ($<5\text{mV}$) crosstalk was observed under blue light for Chrimson.

[0142] Figure 10 illustrates results with example traces of voltage-clamped non-opsin-expressing neurons in layer 2/3 or 5, post-synaptic to opsin-expressing cells. Zero post-synaptic crosstalk was observed for both Chronos and Chrimson under red and blue light illumination respectively. Chronos: blue light 0.13 mW mm^{-2} , red light 1.7 mW mm^{-2} . Chrimson: blue light 0.37 mW mm^{-2} , red light 1.7 mW mm^{-2} .

[0143] Figure 11 illustrates results of studies of paired-pulse illumination in slice that differentially express Chrimson and Chronos in separate neurons. Fig. 11A shows a triple plasmid *in utero* electroporation scheme used to obtain non-overlapping expression of Chrimson and Chronos. Fig. 11B shows opsin expression in visual cortex no overlap of GFP and mO2 was observed ratio of Chronos to Chrimson labeling could be tuned by titrating Cre plasmid. Fig. 11C shows voltage-clamped non-opsin-expressing neuron in layer 2/3 paired-pulse stimulation to demonstrate different synapses were selectively driven by blue and red light. blue: 0.2 mW mm^{-2} ; red: 5 mW mm^{-2} .

Example 11

[0144] Chrimson light-activated ion channels (ChR88) were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 12 illustrated results that showed that Chrimson could drive spikes in the far-red (660 nm) using 5 ms pulses at 2.6 mW mm^{-2} in cultured hippocampal neurons.

Example 12

[0145] Substituted Chrimson (ChR88) light activated ion channels, referred to as "ChR88 K176R", having an amino acid sequence set forth as SEQ ID NO:5, were expressed in cultured hippocampal neurons using neuron culture, transfection, infection, and imaging methods described in Example 1. *In vitro* whole cell patch clamp recording and optical stimulation were conducted on the neurons using methods described in Example 1. Figure 13 show results indicating that the ChR88 K176R mutant had improved kinetics (13ms tau off) and could mediate high frequency spikes in cultured hippocampal neurons. Examples of current clamped

traces of a single ChR88 K176R expressing neuron are shown. Fig. 13A shows that ChR88 K176R could reliably drive spikes from 1 to 10 mW mm⁻² at 625nm 5Hz stimulation. Fig. 13B shows red light (625nm) driven spike trains at various frequencies for ChR88 K176R. 1 mW mm⁻² light power is used for all frequencies. Fig. 13C shows current injection control that demonstrated that the neuron was capable of spiking at the indicated frequencies.

Example 13

[0146] Ion conductance recording methods set forth in Example 1, were used to examine channel closing kinetics for ChR88, ChR90, ChR87, and ChR2 expressed in HEK293 cells. The closing kinetics were examined and compared. 2ms light pulse was used to activate channelrhodopsin and all measurements were voltage clamped to -65 mV. Chronos had the fastest channel closing kinetics and is independent of voltage.

Example 14

[0147] Genes described under (a), (b) and (c) were expressed in cells using methods provided below.

Genes

[0148]

1. a) The *Chloromonas subdivisa* gene referred to herein as ChR87 and having the amino acid sequence set forth herein as SEQ ID NO:5 and a mammalian codon-optimized DNA sequence set forth herein as SEQ ID NO:6;
2. b) The gene for *Chlamydomonas noctigama* referred to herein as ChR88 or Chrimson, and having the amino acid sequence set forth herein as SEQ ID NO:1 and a mammalian codon-optimized DNA sequence set forth herein as SEQ ID NO:2; and
3. c) The gene for *Stigeoclonium helveticum*, referred to herein as ChR90 or Chronos and having the amino acid sequence set forth herein as SEQ ID NO:3 and having a mammalian codon-optimized DNA sequence set forth herein as SEQ ID NO:4 are expressed in cells as follows.

Methods

[0149]

1. (1) The opsin gene was cloned into a lentiviral or adeno-associated virus (AAV) packaging plasmid, or another desired expression plasmid, and then clone GFP downstream of the preferred gene, eliminating the stop codon of the opsin gene, thus creating a fusion protein.
2. (2) The viral or expression plasmid contained either a strong general promoter, a cell-specific promoter, or a strong general promoter followed by one more logical elements (such as a lox-stop-lox sequence, which will be removed by Cre recombinase selectively expressed in cells in a transgenic animal, or in a second virus, thus enabling the strong general promoter to then drive the gene.
3. (3) If using a viral plasmid, synthesize the viral vector using the viral plasmid.
4. (4) If using a virus, as appropriate for gene therapy (over 600 people have been treated with AAV carrying various genetic payloads to date, in 48 separate clinical trials, without a single adverse event), inject the virus using a small needle or cannula into the area of interest, thus delivering the gene encoding the opsin fusion protein into the cells of interest. If using another expression vector, directly electroporate or inject that vector into the cell or organism (for acutely expressing the opsin, or making a cell line, or a transgenic mouse or other animal).
5. (5) Illuminate with light. For Chronos, peak illumination wavelengths are 500 nm $\pm$ 15 nm. For Chrimson, peak illumination wavelengths are 590 nm $\pm$ 15 nm.
6. (6) To illuminate two different populations of cells (e.g., in a single tissue) with two different colors of light, first target one population with Chrimson, and the other population with Chronos, using two different viruses (e.g., with different coat proteins or promoters) or two different plasmids (e.g., with two different promoters). Then, after the molecule expresses, illuminate the tissue with 470 $\pm$ 10 nm or 406 $\pm$ 10 nm light to preferentially depolarize the Chronos-expressing cells, and illuminate the tissue with 406 $\pm$ 10 nm or 660 $\pm$ 10 nm light, to preferentially depolarize the Chrimson-expressing cells.
7. (7) The above wavelengths illustrate typical modes of operation, but are not meant to constrain the protocols that can be used. Either narrower or broader wavelengths, or differently-centered illumination spectra, can be used. For prosthetic uses, the devices used to deliver light may be implanted. For drug screening, a xenon lamp or LED can be used to deliver the light.

[0150] Aspects of the invention include compositions of matter that have been reduced to practice, as described below:

Plasmids encoding for the above genes, have been prepared and used to deliver genes into cells, where the genes have been expressed. As an exemplary vector, lentiviruses carrying payloads encoding for the above genes have been prepared and used to deliver genes into cells resulting in expression of the light activated ion channels in the cells. In addition, adeno-associated viruses carrying payloads encoding for the above genes have been prepared and used to deliver genes into cells, resulting in the expression of the light activated ion channels in the cells. Cells have been prepared that express the light activated ion channels genes set

forth in Example 2. Animals have been prepared that include cells that express the light activated ion channels genes disclosed herein.

Example 15

[0151] Two-color assays are performed. Chronos (for blue light activation) and Chrimson (for red light activation) are expressed in separate sets cells that represent non-overlapping neuronal populations. Following expression, the cell population is exposed to light and the wavelength and timing and "dose" of light is optimized using the following parameters.

[0152] The population is contacted with blue light having a wavelength between 450 nm to 500 nm, and with a pulse width of between 1 and 5 ms for activation. A pulse width of 5 ms provides for minimum sub-threshold crosstalk in the blue light, which is defined as <15 mV, <10 mV, and optimally as <5 mV.

1. (1) The maximum blue light power that can be used is determined using by patch clamping Chrimson expressing cells, illuminating with blue light and measuring voltage deflection. Optimally using blue light power such that maximum voltage deflection is <10mV, usually 0.4 to 0.6mW/mm².
2. (2) The optimal blue light power that can be used to drive Chronos is determined using the same conditions as above in (1), except using lower light power, such as 50uW/mm² to 0.4mW/mm², and optimally 0.2mW/mm². Power depends on expression system and cell type used in the study.

[0153] The population is contacted with red light having a wavelength between 620 nm to 640nm, and with a pulse width of between 1 and 5 ms for activation, which may be optimized at 5ms. The optimal light power to drive chrimson in the red is determined by ramping light powers from 0.5mW/mm² to 10mW/mm². The method is optimized such that a minimum red light power is used to achieve 100% spiking for chrimson.

SEQUENCE LISTING

[0154]

<110> Massachusetts Institute of Technology The Governors of the University of Alberta

<120> CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS

<130> YCJ73309P.EPPD1

<140>

<141> 2012-11-12

<150> PCT/US2012/064665

<151> 2012-11-12

<150> 61/559076

<151> 2011-11-12

<160> 25

<170> PatentIn version 3.5

<210> 1

<211> 669

<212> PRT

<213> Chlamydomonas noctigama

<400> 1

Met Ala Glu Leu Ile Ser Ser Ala Thr Arg Ser Leu Phe Ala Ala Gly
 1 5 10 15

Gly Ile Asn Pro Trp Pro Asn Pro Tyr His His Glu Asp Met Gly Cys
 20 25 30

Gly Gly Met Thr Pro Thr Gly Glu Cys Phe Ser Thr Glu Trp Trp Cys
 35 40 45

Asp Pro Ser Tyr Gly Leu Ser Asp Ala Gly Tyr Gly Tyr Cys Phe Val
 50 55 60

Glu Ala Thr Gly Gly Tyr Leu Val Val Gly Val Glu Lys Lys Gln Ala
 65 70 75 80

Trp Leu His Ser Arg Gly Thr Pro Gly Glu Lys Ile Gly Ala Gln Val
 85 90 95

Cys Gln Trp Ile Ala Phe Ser Ile Ala Ile Ala Leu Leu Thr Phe Tyr
 100 105 110

Gly Phe Ser Ala Trp Lys Ala Thr Cys Gly Trp Glu Glu Val Tyr Val
 115 120 125

Cys Cys Val Glu Val Leu Phe Val Thr Leu Glu Ile Phe Lys Glu Phe

130

135

140

Ser Ser Pro Ala Thr Val Tyr Leu Ser Thr Gly Asn His Ala Tyr Cys
 145 150 155 160

Leu Arg Tyr Phe Glu Trp Leu Leu Ser Cys Pro Val Ile Leu Ile Lys
 165 170 175

```

Leu Ser Asn Leu Ser Gly Leu Lys Asn Asp Tyr Ser Lys Arg Thr Met
    180                      185                      190

Gly Leu Ile Val Ser Cys Val Gly Met Ile Val Phe Gly Met Ala Ala
    195                      200                      205

Gly Leu Ala Thr Asp Trp Leu Lys Trp Leu Leu Tyr Ile Val Ser Cys
    210                      215                      220

Ile Tyr Gly Gly Tyr Met Tyr Phe Gln Ala Ala Lys Cys Tyr Val Glu
    225                      230                      235                      240

Ala Asn His Ser Val Pro Lys Gly His Cys Arg Met Val Val Lys Leu
    245                      250                      255

Met Ala Tyr Ala Tyr Phe Ala Ser Trp Gly Ser Tyr Pro Ile Leu Trp
    260                      265                      270

Ala Val Gly Pro Glu Gly Leu Leu Lys Leu Ser Pro Tyr Ala Asn Ser
    275                      280                      285

Ile Gly His Ser Ile Cys Asp Ile Ile Ala Lys Glu Phe Trp Thr Phe
    290                      295                      300

Leu Ala His His Leu Arg Ile Lys Ile His Glu His Ile Leu Ile His
    305                      310                      315                      320

Gly Asp Ile Arg Lys Thr Thr Lys Met Glu Ile Gly Gly Glu Glu Val
    325                      330                      335

Glu Val Glu Glu Phe Val Glu Glu Glu Asp Glu Asp Thr Val Thr His
    340                      345                      350

Pro Thr Ser Asn Leu Ala Asn Arg Asn Ser Phe Val Ile Met Ala Glu
    355                      360                      365

Arg Met Arg Ala Arg Gly Ile Asp Val Arg Ala Ser Leu Asp Arg Asn
    370                      375                      380

Gly Pro Met Ile Glu Ser Gly Arg Val Ile Leu Ala Asp Thr Asp Ile
    385                      390                      395                      400

Phe Val Thr Glu Met Phe Lys Ala Gln Phe Ala Gln Leu Pro Ala Ala
    405                      410                      415

Ile Glu Leu Ile Pro Ala Leu Gly Ala Asp Asn Ala Leu Gln Leu Val
    420                      425                      430

Gln Gln Ala Ser Val Leu Gly Gly Cys Asp Phe Val Met Val His Pro
    435                      440                      445

Gln Phe Leu Lys Asp Asn Ser Pro Ser Gly Leu Val Ala Arg Leu Arg
    450                      455                      460

Met Met Gly Gln Arg Val Val Ala Phe Gly Pro Ala Asn Leu Arg Glu
    465                      470                      475                      480

```

Leu Ile Glu Ser Cys Asp Val Asp Ala Trp Ile Glu Ala Pro Pro Ile
 485 490 495
 Asn Leu Tyr Gln Leu Arg Gln Val Val Ala Gln Met Gln Leu Met Arg
 500 505 510
 Arg Gln Ala Ala Met Met Gly Gly Met Gly Gly Gly Met Lys Gly Gly
 515 520 525
 Met Ser Gly Met Gly Met Gly Met His Ala Gly Ser Met Trp Lys Gln
 530 535 540
 Gln Gln Met Met Met Gln Gln Asp Gly Ser Ala Met Met Met Pro Ala
 545 550 555 560
 Met Gln Gly Gly Ala Ala Ser Met Arg Gly Ser Gly Leu Ile Ser Ala
 565 570 575
 Gln Pro Gly Arg Gln Ala Ser Leu Gly Gly Pro Gln Ser Val Met Met
 580 585 590
 Gly Ser Ala Met Val Gly Ser Asn Pro Leu Phe Gly Thr Ala Pro Ser
 595 600 605
 Pro Leu Gly Ser Ala Val Gly Ala Glu Ala Met Gly His Asn Leu Tyr
 610 615 620
 Gly Asn Gln Ala Ala Ala Gly Gly Ile Pro Ala Ala Ser Ala Ala Ala
 625 630 635 640
 Asp Gly Thr Asp Val Glu Met Met Gln Gln Leu Met Ser Glu Ile Asp
 645 650 655
 Arg Leu Lys Gly Glu Leu Gly Glu Gln Asp Met Pro Arg
 660 665
 <210> 2
 <211> 350
 <212> PRT
 <213> Chlamydomonas noctigama
 <400> 2
 Met Ala Glu Leu Ile Ser Ser Ala Thr Arg Ser Leu Phe Ala Ala Gly
 1 5 10 15
 Gly Ile Asn Pro Trp Pro Asn Pro Tyr His His Glu Asp Met Gly Cys
 20 25 30
 Gly Gly Met Thr Pro Thr Gly Glu Cys Phe Ser Thr Glu Trp Trp Cys
 35 40 45
 Asp Pro Ser Tyr Gly Leu Ser Asp Ala Gly Tyr Gly Tyr Cys Phe Val
 50 55 60
 Glu Ala Thr Gly Gly Tyr Leu Val Val Gly Val Glu Lys Lys Gln Ala
 65 70 75 80

Trp Leu His Ser Arg Gly Thr Pro Gly Glu Lys Ile Gly Ala Gln Val
85 90 95

Cys Gln Trp Ile Ala Phe Ser Ile Ala Ile Ala Leu Leu Thr Phe Tyr
100 105 110

Gly Phe Ser Ala Trp Lys Ala Thr Cys Gly Trp Glu Glu Val Tyr Val
115 120 125

Cys Cys Val Glu Val Leu Phe Val Thr Leu Glu Ile Phe Lys Glu Phe
130 135 140

Ser Ser Pro Ala Thr Val Tyr Leu Ser Thr Gly Asn His Ala Tyr Cys
145 150 155 160

Leu Arg Tyr Phe Glu Trp Leu Leu Ser Cys Pro Val Ile Leu Ile Lys
165 170 175

Leu Ser Asn Leu Ser Gly Leu Lys Asn Asp Tyr Ser Lys Arg Thr Met
180 185 190

Gly Leu Ile Val Ser Cys Val Gly Met Ile Val Phe Gly Met Ala Ala
195 200 205

Gly Leu Ala Thr Asp Trp Leu Lys Trp Leu Leu Tyr Ile Val Ser Cys
210 215 220

Ile Tyr Gly Gly Tyr Met Tyr Phe Gln Ala Ala Lys Cys Tyr Val Glu
225 230 235 240

Ala Asn His Ser Val Pro Lys Gly His Cys Arg Met Val Val Lys Leu
245 250 255

Met Ala Tyr Ala Tyr Phe Ala Ser Trp Gly Ser Tyr Pro Ile Leu Trp
260 265 270

Ala Val Gly Pro Glu Gly Leu Leu Lys Leu Ser Pro Tyr Ala Asn Ser
275 280 285

Ile Gly His Ser Ile Cys Asp Ile Ile Ala Lys Glu Phe Trp Thr Phe
290 295 300

Leu Ala His His Leu Arg Ile Lys Ile His Glu His Ile Leu Ile His
305 310 315 320

Gly Asp Ile Arg Lys Thr Thr Lys Met Glu Ile Gly Gly Glu Glu Val
325 330 335

Glu Val Glu Glu Phe Val Glu Glu Glu Asp Glu Asp Thr Val
340 345 350

<210> 3

<211> 1050

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide, Mammalian-condon optimized DNA

<400> 3

```

atggctgagc tgatcagcag cgccaccaga tctctgtttg ccgccggagg catcaaccct      60
tggcctaacc cctaccacca cgaggacatg ggctgtggag gaatgacacc tacaggcgag      120
tgcttcagca ccgagtgggt gtgtgaccct tcttacggac tgagcgacgc cggatacggg      180
tattgcttcg tggaggccac aggcgggtac ctggctcgtg gagtggagaa gaagcaggct      240
tggctgcaca gcagaggcac accaggagaa aagatcggcg ccaggtctg ccagtggatt      300
gctttcagca tcgccatcgc cctgctgaca ttctacggct tcagcgccctg gaaggccact      360
tgcggttggg aggaggtcta cgtctgttgc gtcgaggtgc tgttcgtgac cctggagatc      420
ttcaaggagt tcagcagccc cgccacagtg tacctgtcta ccggcaacca cgcctattgc      480
ctgcgctact tcgagtggct gctgtcttgc cccgtgatcc tgatcaagct gagcaacctg      540
agcggcctga agaacgacta cagcaagcgg accatgggcc tgatcgtgtc ttgcgtggga      600
atgatcgtgt tcggcatggc cgcaggactg gctaccgatt ggctcaagtg gctgctgtat      660
atcgtgtctt gcactctacg cggtacatg tacttccagg ccgccaagtg ctacgtggaa      720
gccaaccaca gcgtgcctaa aggccattgc cgcattggtc tgaagctgat ggcctacgct      780
tacttcgcct cttggggcag ctaccaatc ctctgggcag tgggaccaga aggactgctg      840
aagctgagcc cttacgccaa cagcatcggc cacagcatct gcgacatcat cgccaaggag      900
ttttggacct tcctggccca ccacctgagg atcaagatcc acgagcacat cctgatccac      960
ggcgacatcc ggaagaccac caagatggag atcggaggcg aggaggtgga agtggaagag     1020
ttcgtggagg aggaggacga ggacacagtg                                1050

```

<210> 4

<211> 235

<212> PRT

<213> Chlamydomonas noctigama

<400> 4

```

Gly Thr Pro Gly Glu Lys Ile Gly Ala Gln Val Cys Gln Trp Ile Ala
1          5          10          15

Phe Ser Ile Ala Ile Ala Leu Leu Thr Phe Tyr Gly Phe Ser Ala Trp
20          25          30

Lys Ala Thr Cys Gly Trp Glu Glu Val Tyr Val Cys Cys Val Glu Val
35          40          45

Leu Phe Val Thr Leu Glu Ile Phe Lys Glu Phe Ser Ser Pro Ala Thr
50          55          60

Val Tyr Leu Ser Thr Gly Asn His Ala Tyr Cys Leu Arg Tyr Phe Glu
65          70          75          80

```

Trp Leu Leu Ser Cys Pro Val Ile Leu Ile Lys Leu Ser Asn Leu Ser
85 90 95

Gly Leu Lys Asn Asp Tyr Ser Lys Arg Thr Met Gly Leu Ile Val Ser
100 105 110

Cys Val Gly Met Ile Val Phe Gly Met Ala Ala Gly Leu Ala Thr Asp
115 120 125

Trp Leu Lys Trp Leu Leu Tyr Ile Val Ser Cys Ile Tyr Gly Gly Tyr
130 135 140

Met Tyr Phe Gln Ala Ala Lys Cys Tyr Val Glu Ala Asn His Ser Val
145 150 155 160

Pro Lys Gly His Cys Arg Met Val Val Lys Leu Met Ala Tyr Ala Tyr
165 170 175

Phe Ala Ser Trp Gly Ser Tyr Pro Ile Leu Trp Ala Val Gly Pro Glu
180 185 190

Gly Leu Leu Lys Leu Ser Pro Tyr Ala Asn Ser Ile Gly His Ser Ile
195 200 205

Cys Asp Ile Ile Ala Lys Glu Phe Trp Thr Phe Leu Ala His His Leu
210 215 220

Arg Ile Lys Ile His Glu His Ile Leu Ile His
225 230 235

<210> 5

<211> 350

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 5

Met Ala Glu Leu Ile Ser Ser Ala Thr Arg Ser Leu Phe Ala Ala Gly
1 5 10 15

Gly Ile Asn Pro Trp Pro Asn Pro Tyr His His Glu Asp Met Gly Cys
20 25 30

Gly Gly Met Thr Pro Thr Gly Glu Cys Phe Ser Thr Glu Trp Trp Cys
35 40 45

Asp Pro Ser Tyr Gly Leu Ser Asp Ala Gly Tyr Gly Tyr Cys Phe Val
50 55 60

Glu Ala Thr Gly Gly Tyr Leu Val Val Gly Val Glu Lys Lys Gln Ala
65 70 75 80

Trp Leu His Ser Arg Gly Thr Pro Gly Glu Lys Ile Gly Ala Gln Val
85 90 95

Cys Gln Trp Ile Ala Phe Ser Ile Ala Ile Ala Leu Leu Thr Phe Tyr
100 105 110

Gly Phe Ser Ala Trp Lys Ala Thr Cys Gly Trp Glu Glu Val Tyr Val
115 120 125

Cys Cys Val Glu Val Leu Phe Val Thr Leu Glu Ile Phe Lys Glu Phe
130 135 140

Ser Ser Pro Ala Thr Val Tyr Leu Ser Thr Gly Asn His Ala Tyr Cys
145 150 155 160

Leu Arg Tyr Phe Glu Trp Leu Leu Ser Cys Pro Val Ile Leu Ile Arg
165 170 175

Leu Ser Asn Leu Ser Gly Leu Lys Asn Asp Tyr Ser Lys Arg Thr Met
180 185 190

Gly Leu Ile Val Ser Cys Val Gly Met Ile Val Phe Gly Met Ala Ala
195 200 205

Gly Leu Ala Thr Asp Trp Leu Lys Trp Leu Leu Tyr Ile Val Ser Cys
210 215 220

Ile Tyr Gly Gly Tyr Met Tyr Phe Gln Ala Ala Lys Cys Tyr Val Glu
225 230 235 240

Ala Asn His Ser Val Pro Lys Gly His Cys Arg Met Val Val Lys Leu
245 250 255

Met Ala Tyr Ala Tyr Phe Ala Ser Trp Gly Ser Tyr Pro Ile Leu Trp
260 265 270

Ala Val Gly Pro Glu Gly Leu Leu Lys Leu Ser Pro Tyr Ala Asn Ser
275 280 285

Ile Gly His Ser Ile Cys Asp Ile Ile Ala Lys Glu Phe Trp Thr Phe
290 295 300

Leu Ala His His Leu Arg Ile Lys Ile His Glu His Ile Leu Ile His
305 310 315 320

Gly Asp Ile Arg Lys Thr Thr Lys Met Glu Ile Gly Gly Glu Glu Val
325 330 335

Glu Val Glu Glu Phe Val Glu Glu Glu Asp Glu Asp Thr Val
340 345 350

<210> 6

<211> 421

<212> PRT

<213> Stigeoclonium helveticum

<400> 6

```

Met Glu Thr Ala Ala Thr Met Thr His Ala Phe Ile Ser Ala Val Pro
 1              5              10              15

Ser Ala Glu Ala Thr Ile Arg Gly Leu Leu Ser Ala Ala Ala Val Val
      20              25              30

Thr Pro Ala Ala Asp Ala His Gly Glu Thr Ser Asn Ala Thr Thr Ala
      35              40              45

Gly Ala Asp His Gly Cys Phe Pro His Ile Asn His Gly Thr Glu Leu
 50              55              60

Gln His Lys Ile Ala Val Gly Leu Gln Trp Phe Thr Val Ile Val Ala
65              70              75              80

Ile Val Gln Leu Ile Phe Tyr Gly Trp His Ser Phe Lys Ala Thr Thr
      85              90              95

Gly Trp Glu Glu Val Tyr Val Cys Val Ile Glu Leu Val Lys Cys Phe
      100              105              110

Ile Glu Leu Phe His Glu Val Asp Ser Pro Ala Thr Val Tyr Gln Thr
      115              120              125

Asn Gly Gly Ala Val Ile Trp Leu Arg Tyr Ser Met Trp Leu Leu Thr
      130              135              140

Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr Gly Leu His Glu
      145              150              155              160

Glu Tyr Ser Lys Arg Thr Met Thr Ile Leu Val Thr Asp Ile Gly Asn
      165              170              175

Ile Val Trp Gly Ile Thr Ala Ala Phe Thr Lys Gly Pro Leu Lys Ile
      180              185              190

Leu Phe Phe Met Ile Gly Leu Phe Tyr Gly Val Thr Cys Phe Phe Gln
      195              200              205

Ile Ala Lys Val Tyr Ile Glu Ser Tyr His Thr Leu Pro Lys Gly Val
      210              215              220

Cys Arg Lys Ile Cys Lys Ile Met Ala Tyr Val Phe Phe Cys Ser Trp
      225              230              235              240

Leu Met Phe Pro Val Met Phe Ile Ala Gly His Glu Gly Leu Gly Leu
      245              250              255

Ile Thr Pro Tyr Thr Ser Gly Ile Gly His Leu Ile Leu Asp Leu Ile
      260              265              270

Ser Lys Asn Thr Trp Gly Phe Leu Gly His His Leu Arg Val Lys Ile
      275              280              285

```

His Glu His Ile Leu Ile His Gly Asp Ile Arg Lys Thr Thr Thr Ile
290 295 300

Asn Val Ala Gly Glu Asn Met Glu Ile Glu Thr Phe Val Asp Glu Glu
305 310 315 320

Glu Glu Gly Gly Val Asn His Gly Thr Ala Asp Leu Ala His Arg Ala
325 330 335

Ser Phe Gln Lys Met Gly Asp Arg Leu Arg Ala Gln Gly Val Thr Val
340 345 350

Arg Ala Ser Leu Asp Ala His Glu Val Pro Pro Ala Asp Glu Glu Asn
355 360 365

Lys Phe Ala Gln Lys Ser Ala Ala Ala Asn Met Pro Ala Tyr Asn Pro
370 375 380

Gly Lys Val Ile Leu Ile Val Pro Asp Met Ser Met Val Asp Tyr Phe
385 390 395 400

Arg Asp Gln Phe Glu Gln Leu Pro Thr Arg Met Glu Leu Leu Pro Ala
405 410 415

Leu Gly Met Asp Thr
420

<210> 7

<211> 325

<212> PRT

<213> Stigeoclonium helveticum

<400> 7

Met Glu Thr Ala Ala Thr Met Thr His Ala Phe Ile Ser Ala Val Pro
1 5 10 15

Ser Ala Glu Ala Thr Ile Arg Gly Leu Leu Ser Ala Ala Ala Val Val
20 25 30

Thr Pro Ala Ala Asp Ala His Gly Glu Thr Ser Asn Ala Thr Thr Ala
35 40 45

Gly Ala Asp His Gly Cys Phe Pro His Ile Asn His Gly Thr Glu Leu
50 55 60

Gln His Lys Ile Ala Val Gly Leu Gln Trp Phe Thr Val Ile Val Ala
65 70 75 80

Ile Val Gln Leu Ile Phe Tyr Gly Trp His Ser Phe Lys Ala Thr Thr
85 90 95

Gly Trp Glu Glu Val Tyr Val Cys Val Ile Glu Leu Val Lys Cys Phe
100 105 110

Ile Glu Leu Phe His Glu Val Asp Ser Pro Ala Thr Val Tyr Gln Thr
 115 120 125
 Asn Gly Gly Ala Val Ile Trp Leu Arg Tyr Ser Met Trp Leu Leu Thr
 130 135 140
 Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr Gly Leu His Glu
 145 150 155 160
 Glu Tyr Ser Lys Arg Thr Met Thr Ile Leu Val Thr Asp Ile Gly Asn
 165 170 175
 Ile Val Trp Gly Ile Thr Ala Ala Phe Thr Lys Gly Pro Leu Lys Ile
 180 185 190
 Leu Phe Phe Met Ile Gly Leu Phe Tyr Gly Val Thr Cys Phe Phe Gln
 195 200 205
 Ile Ala Lys Val Tyr Ile Glu Ser Tyr His Thr Leu Pro Lys Gly Val
 210 215 220
 Cys Arg Lys Ile Cys Lys Ile Met Ala Tyr Val Phe Phe Cys Ser Trp
 225 230 235 240
 Leu Met Phe Pro Val Met Phe Ile Ala Gly His Glu Gly Leu Gly Leu
 245 250 255
 Ile Thr Pro Tyr Thr Ser Gly Ile Gly His Leu Ile Leu Asp Leu Ile
 260 265 270
 Ser Lys Asn Thr Trp Gly Phe Leu Gly His His Leu Arg Val Lys Ile
 275 280 285
 His Glu His Ile Leu Ile His Gly Asp Ile Arg Lys Thr Thr Thr Ile
 290 295 300
 Asn Val Ala Gly Glu Asn Met Glu Ile Glu Thr Phe Val Asp Glu Glu
 305 310 315 320
 Glu Glu Gly Gly Val
 325

<210> 8

<211> 975

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide, Mammalian-condon optimized DNA

<400> 8

atggaaacag cgcacacaat gacccacgcc tttatctcag ccgtgcctag cgccgaagcc	60
acaattagag gcctgctgag cgccgcagca gtggtgacac cagcagcaga cgctcacgga	120
gaaacctcta acgccacaac agccggagcc gatcacggtt gcttcccca catcaaccac	180
ccacacacac tggacacacac gctggagcga ggaatgagct gcttgcagct gctgctgagct	240

```

yyaaccyagc tgcagacaaa gatcgcagtg ggaaccagc ggtccaccgt gatcgtggc 240
atcgtgcagc tcattcttcta cggttggcac agcttcaagg ccacaaccgg ctgggaggag 300
gtctacgtct gcgtgatcga gctcgtcaag tgcttcatcg agctgttcca cgaggtcgac 360
agcccagcca cagtgtacca gaccaacgga ggagccgtga tttggctgcg gtacagcatg 420
tggctcctga cttgccccgt gatcctgatc cacctgagca acctgaccgg actgcacgaa 480
gagtacagca agcggaccat gaccatcctg gtgaccgaca tcggcaacat cgtgtggggg 540
atcacagccg cctttacaaa gggccccctg aagatcctgt tcttcatgat cggcctgttc 600
tacggcgtga cttgcttctt ccagatcgcc aaggtgtata tcgagagcta ccacaccctg 660
cccaaaggcg tctgcccga gatttgcaag atcatggcct acgtcttctt ctgctcttgg 720
ctgatgttcc ccgtgatgtt catcgccgga cagcagggac tgggcctgat cacaccttac 780
accagcggaa tcggccacct gatcctggat ctgatcagca agaacacttg gggcttcctg 840
ggccaccacc tgagagtga gatccacgag cacatcctga tccacggcga catccggaag 900
acaaccacca tcaacgtggc cggcgagaac atggagatcg agaccttcgt cgacgaggag 960
gaggaggagg gagg 975

```

<210> 9

<211> 235

<212> PRT

<213> *Stigeoclonium helveticum*

<400> 9

```

Gly Thr Glu Leu Gln His Lys Ile Ala Val Gly Leu Gln Trp Phe Thr
1           5           10          15

Val Ile Val Ala Ile Val Gln Leu Ile Phe Tyr Gly Trp His Ser Phe
20          25          30

Lys Ala Thr Thr Gly Trp Glu Glu Val Tyr Val Cys Val Ile Glu Leu
35          40          45

Val Lys Cys Phe Ile Glu Leu Phe His Glu Val Asp Ser Pro Ala Thr
50          55          60

Val Tyr Gln Thr Asn Gly Gly Ala Val Ile Trp Leu Arg Tyr Ser Met
65          70          75          80

Trp Leu Leu Thr Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr
85          90          95

Gly Leu His Glu Glu Tyr Ser Lys Arg Thr Met Thr Ile Leu Val Thr
100         105         110

Asp Ile Gly Asn Ile Val Trp Gly Ile Thr Ala Ala Phe Thr Lys Gly
115         120         125

Pro Leu Lys Ile Leu Phe Phe Met Ile Gly Leu Phe Tyr Gly Val Thr
130         135         140

Glu Phe Phe Glu Ile Ala Val Thr Thr Ile Glu Ser Thr His Thr Thr
145         150         155         160         165         170

```

Cys Phe Phe Gln Ile Ala Lys Val Tyr Ile Glu Ser Tyr His Thr Leu
145 150 155 160

Pro Lys Gly Val Cys Arg Lys Ile Cys Lys Ile Met Ala Tyr Val Phe
165 170 175

Phe Cys Ser Trp Leu Met Phe Pro Val Met Phe Ile Ala Gly His Glu
180 185 190

Gly Leu Gly Leu Ile Thr Pro Tyr Thr Ser Gly Ile Gly His Leu Ile
195 200 205

Leu Asp Leu Ile Ser Lys Asn Thr Trp Gly Phe Leu Gly His His Leu
210 215 220

Arg Val Lys Ile His Glu His Ile Leu Ile His
225 230 235

<210> 10

<211> 457

<212> PRT

<213> Chloromonas subdivisa

<400> 10

Met Ser Arg Leu Val Ala Ala Ser Trp Leu Leu Ala Leu Leu Leu Cys
1 5 10 15

Gly Ile Thr Ser Thr Thr Thr Ala Ser Ser Ala Pro Ala Ala Ser Ser
20 25 30

Thr Asp Gly Thr Ala Ala Ala Ala Val Ser His Tyr Ala Met Asn Gly
35 40 45

Phe Asp Glu Leu Ala Lys Gly Ala Val Val Pro Glu Asp His Phe Val
50 55 60

Cys Gly Pro Ala Asp Lys Cys Tyr Cys Ser Ala Trp Leu His Ser His
65 70 75 80

Gly Ser Lys Glu Glu Lys Thr Ala Phe Thr Val Met Gln Trp Ile Val
85 90 95

Phe Ala Val Cys Ile Ile Ser Leu Leu Phe Tyr Ala Tyr Gln Thr Trp
100 105 110

Arg Ala Thr Cys Gly Trp Glu Glu Val Tyr Val Thr Ile Ile Glu Leu
115 120 125

Val His Val Cys Phe Gly Leu Trp His Glu Val Asp Ser Pro Cys Thr
130 135 140

Leu Tyr Leu Ser Thr Gly Asn Met Val Leu Trp Leu Arg Tyr Ala Glu
145 150 155 160

Trp Leu Leu Thr Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr
165 170 175

```

      ---      ---      ---
Gly Met Lys Asn Asp Tyr Asn Lys Arg Thr Met Ala Leu Leu Val Ser
      180      185      190

Asp Val Gly Cys Ile Val Trp Gly Thr Thr Ala Ala Leu Ser Thr Asp
      195      200      205

Phe Val Lys Ile Ile Phe Phe Phe Leu Gly Leu Leu Tyr Gly Phe Tyr
      210      215      220

Thr Phe Tyr Ala Ala Ala Lys Ile Tyr Ile Glu Ala Tyr His Thr Val
      225      230      235      240

Pro Lys Gly Ile Cys Arg Gln Leu Val Arg Leu Gln Ala Tyr Asp Phe
      245      250      255

Phe Phe Thr Trp Ser Met Phe Pro Ile Leu Phe Met Val Gly Pro Glu
      260      265      270

Gly Phe Gly Lys Ile Thr Ala Tyr Ser Ser Gly Ile Ala His Glu Val
      275      280      285

Cys Asp Leu Leu Ser Lys Asn Leu Trp Gly Leu Met Gly His Phe Ile
      290      295      300

Arg Val Lys Ile His Glu His Ile Leu Val His Gly Asn Ile Thr Lys
      305      310      315      320

Lys Thr Lys Val Asn Val Ala Gly Asp Met Val Glu Leu Asp Thr Tyr
      325      330      335

Val Asp Gln Asp Glu Glu His Asp Glu Gly Thr Ile Asp Arg Gly Thr
      340      345      350

Gln Glu Leu Ala Asn Arg His Ser Phe Val Val Met Arg Glu Asn Met
      355      360      365

Arg Ala Lys Gly Val Asp Val Arg Ala Ser Leu Gly Asp Ile Asp Gly
      370      375      380

Thr Glu Met Thr Lys Ala Gly Asn Met Asn Gly Thr Leu Glu Pro Gly
      385      390      395      400

Arg Ile Ile Leu Cys Val Pro Asp Met Ser Leu Val Asp Phe Phe Arg
      405      410      415

Glu Gln Phe Ser Gln Met Pro Val Pro Phe Glu Val Val Pro Ala Leu
      420      425      430

Gly Pro Glu Val Ala Leu Gln Leu Val Gln Gln Ala Leu Ser Ile Gly
      435      440      445

Gly Ala Asn Tyr Ile Asp Tyr Val Met
      450      455

```

<210> 11

<211> 346

<212> PRT

<213> Chloromonas subdivisa

<400> 11

Met Ser Arg Leu Val Ala Ala Ser Trp Leu Leu Ala Leu Leu Leu Cys
 1 5 10 15

Gly Ile Thr Ser Thr Thr Thr Ala Ser Ser Ala Pro Ala Ala Ser Ser
 20 25 30

Thr Asp Gly Thr Ala Ala Ala Ala Val Ser His Tyr Ala Met Asn Gly
 35 40 45

Phe Asp Glu Leu Ala Lys Gly Ala Val Val Pro Glu Asp His Phe Val
 50 55 60

Cys Gly Pro Ala Asp Lys Cys Tyr Cys Ser Ala Trp Leu His Ser His
 65 70 75 80

Gly Ser Lys Glu Glu Lys Thr Ala Phe Thr Val Met Gln Trp Ile Val
 85 90 95

Phe Ala Val Cys Ile Ile Ser Leu Leu Phe Tyr Ala Tyr Gln Thr Trp
 100 105 110

Arg Ala Thr Cys Gly Trp Glu Glu Val Tyr Val Thr Ile Ile Glu Leu
 115 120 125

Val His Val Cys Phe Gly Leu Trp His Glu Val Asp Ser Pro Cys Thr
 130 135 140

Leu Tyr Leu Ser Thr Gly Asn Met Val Leu Trp Leu Arg Tyr Ala Glu
 145 150 155 160

Trp Leu Leu Thr Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr
 165 170 175

Gly Met Lys Asn Asp Tyr Asn Lys Arg Thr Met Ala Leu Leu Val Ser
 180 185 190

Asp Val Gly Cys Ile Val Trp Gly Thr Thr Ala Ala Leu Ser Thr Asp
 195 200 205

Phe Val Lys Ile Ile Phe Phe Phe Leu Gly Leu Leu Tyr Gly Phe Tyr
 210 215 220

Thr Phe Tyr Ala Ala Ala Lys Ile Tyr Ile Glu Ala Tyr His Thr Val

225 230 235 240

Pro Lys Gly Ile Cys Arg Gln Leu Val Arg Leu Gln Ala Tyr Asp Phe
 245 250 255

Phe Phe Thr Trp Ser Met Phe Pro Ile Leu Phe Met Val Gly Pro Glu
260 265 270

Gly Phe Gly Lys Ile Thr Ala Tyr Ser Ser Gly Ile Ala His Glu Val
275 280 285

Cys Asp Leu Leu Ser Lys Asn Leu Trp Gly Leu Met Gly His Phe Ile
290 295 300

Arg Val Lys Ile His Glu His Ile Leu Val His Gly Asn Ile Thr Lys
305 310 315 320

Lys Thr Lys Val Asn Val Ala Gly Asp Met Val Glu Leu Asp Thr Tyr
325 330 335

Val Asp Gln Asp Glu Glu His Asp Glu Gly
340 345

<210> 12

<211> 1038

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide, Mammalian-codon optimized DNA

<400> 12

atgagcagac tggtcgccgc ttcttggctg ctggctctcc tcctctgcgg aattaccagc	60
acaacaacag cctctagcgc cccagcagct tcttctacag acggaacagc cgccgcagca	120
gtgtctcact acgcatgaa cggcttcgac gagctggcta aaggagccgt ggtgccagaa	180
gaccactttg tctgcggacc agccgacaag tgctattgct ccgcttggct gcacagccac	240
ggaagcaagg aggagaagac cgccttcacc gtcatgcagt ggatcgtgtt cgcctctgc	300
atcatcagcc tgctgttcta cgcctaccag acttggaggg ctacttgcgg ttgggaggag	360
gtgtacgtga ccatcatcga gctggccac gtctgcttcg gactctggca cgaggtcgat	420
agcccttgta ccctgtacct gagcacaggc aacatggctc tctggctgag atacgccgag	480
tggctgctga cttgccccgt gatcctgatc cacctgagca acctgaccgg catgaagaac	540
gactacaaca agcggaccat ggccctgctg gtgtcagacg tgggctgtat cgtgtgggga	600
acaacagccg ccctgagcac cgatttcgtg aagatcatct tcttcttcct gggcctgctg	660
tacggcttct acaccttcta cgcgcgccgc aagatctaca tcgaggccta ccacaccgtg	720
ccaagggca tttgtagaca gctcgtgcgg ctgcaggcct acgacttctt cttcacttgg	780
agcatgttcc ccatcctgtt catggtcggc ccagagggat tcggcaagat caccgcctac	840
agcagcggaa tcgccacga agtgtgcgat ctgctgagca agaacctctg gggcctgatg	900
ggccacttca tccgcgtgaa gatccacgag cacatcctgg tgcacggcaa catcaccaag	960
aagaccaagg tcaacgtggc cggcgacatg gtggaactgg acacctacgt ggaccaggac	1020

gaggaacacg acgagggga

1038

<210> 13

<211> 235

<212> PRT

<213> Chloromonas subdivisa

<400> 13

Gly Ser Lys Glu Glu Lys Thr Ala Phe Thr Val Met Gln Trp Ile Val
 1 5 10 15

Phe Ala Val Cys Ile Ile Ser Leu Leu Phe Tyr Ala Tyr Gln Thr Trp
 20 25 30

Arg Ala Thr Cys Gly Trp Glu Glu Val Tyr Val Thr Ile Ile Glu Leu
 35 40 45

Val His Val Cys Phe Gly Leu Trp His Glu Val Asp Ser Pro Cys Thr
 50 55 60

Leu Tyr Leu Ser Thr Gly Asn Met Val Leu Trp Leu Arg Tyr Ala Glu
 65 70 75 80

Trp Leu Leu Thr Cys Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr
 85 90 95

Gly Met Lys Asn Asp Tyr Asn Lys Arg Thr Met Ala Leu Leu Val Ser
 100 105 110

Asp Val Gly Cys Ile Val Trp Gly Thr Thr Ala Ala Leu Ser Thr Asp
 115 120 125

Phe Val Lys Ile Ile Phe Phe Phe Leu Gly Leu Leu Tyr Gly Phe Tyr
 130 135 140

Thr Phe Tyr Ala Ala Ala Lys Ile Tyr Ile Glu Ala Tyr His Thr Val
 145 150 155 160

Pro Lys Gly Ile Cys Arg Gln Leu Val Arg Leu Gln Ala Tyr Asp Phe
 165 170 175

Phe Phe Thr Trp Ser Met Phe Pro Ile Leu Phe Met Val Gly Pro Glu
 180 185 190

Gly Phe Gly Lys Ile Thr Ala Tyr Ser Ser Gly Ile Ala His Glu Val
 195 200 205

Cys Asp Leu Leu Ser Lys Asn Leu Trp Gly Leu Met Gly His Phe Ile
 210 215 220

Arg Val Lys Ile His Glu His Ile Leu Val His
 225 230 235

<210> 14

<211> 310

<212> PRT

<213> Neochlorosarcina

<400> 14

Met Ala Asp Phe Val Trp Gln Gly Ala Gly Asn Gly Gly Pro Ser Ala
 1 5 10 15

Met Val Ser His Tyr Pro Asn Gly Ser Val Leu Leu Glu Ser Ser Gly
 20 25 30

Ser Cys Tyr Cys Glu Asp Trp Tyr Thr Ser Arg Gly Asn His Val Glu
 35 40 45

His Ser Leu Ser Asn Ala Cys Asp Trp Phe Ala Phe Ala Ile Ser Val
 50 55 60

Ile Phe Leu Val Tyr Tyr Ala Trp Ala Ala Phe Asn Ser Ser Val Gly
 65 70 75 80

Trp Glu Glu Ile Tyr Val Cys Thr Val Glu Leu Ile Lys Val Ser Ile
 85 90 95

Asp Gln Phe Leu Ser Ser Asn Ser Pro Cys Thr Leu Tyr Leu Ser Thr
 100 105 110

Gly Asn Arg Val Leu Trp Ile Arg Tyr Gly Glu Trp Leu Leu Thr Cys
 115 120 125

Pro Val Ile Leu Ile His Leu Ser Asn Val Thr Gly Leu Lys Asp Asn
 130 135 140

Tyr Ser Lys Arg Thr Met Ala Leu Leu Val Ser Asp Ile Gly Thr Ile
 145 150 155 160

Val Phe Gly Val Thr Ser Ala Met Cys Thr Gly Tyr Pro Lys Val Ile
 165 170 175

Phe Phe Ile Leu Gly Cys Cys Tyr Gly Ala Asn Thr Phe Phe Asn Ala
 180 185 190

Ala Lys Val Tyr Leu Glu Ala His His Thr Leu Pro Lys Gly Ser Cys
 195 200 205

Arg Thr Leu Ile Arg Leu Met Ala Tyr Thr Tyr Tyr Ala Ser Trp Gly
 210 215 220

Met Phe Pro Ile Leu Phe Val Leu Gly Pro Glu Ser Phe Gly His Met
 225 230 235 240

Asn Met Tyr Gln Ser Asn Ile Ala His Thr Val Ile Asp Leu Met Ser
 245 250 255

Lys Asn Ile Trp Gly Met Leu Gly His Phe Leu Arg His Lys Ile Arg
 260 265 270

Glu His Ile Leu Ile His Gly Asp Leu Arg Thr Thr Thr Val Asn
 275 280 285

Val Ala Gly Glu Glu Met Gln Val Glu Thr Met Val Ala Ala Glu Asp
 290 295 300

Ala Asp Glu Thr Thr Val
 305 310

<210> 15

<211> 930

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide; Mammalian-condon optimized DNA

<400> 15

atggccgact tcgtgtggca gggagctgga aacggaggac caagcgccat ggtgtccac	60
taccccaatg gcagcgtgct gctggagagc tccggcagct gctactgtga agactggtat	120
acttctcggg gcaaccacgt ggagcattct ctgagtaatg cttgcgattg gttcgctttt	180
gctatcagcg tgattttcct ggtgtactat gcctgggcg cttttaactc tagtgtgggc	240
tgggaggaaa tctacgtgtg caccgtggag ctgatcaagg tgagcattga tcagttcctg	300
agctccaact ctccttgtac cctgtacctg agtacaggga atagggtgct gtggatcaga	360
tatggcgaat ggctgctgac ttgtccagtg atcctgattc acctgtccaa cgtgacaggg	420
ctgaaggaca attactctaa acgcactatg gctctgctgg tgagtatat cgggaccatc	480
gtgttcggcg tgactttctgc catgtgcacc ggatacccca aagtgatctt ctttattctg	540
ggctgctggt atggagctaa cacattcttt aatgccgcta aggtgtacct ggaggccac	600
catacactgc ctaaaggctc ttgtaggact ctgatcagac tgatggccta tacctactat	660
gctagttggg gaatgttccc cattctgttt gtgctgggac ctgagagctt cggccacatg	720
aacatgtacc agtccaatat cgcccatacc gtgattgacc tgatgtccaa gaacatctgg	780
ggaatgctgg ggcactttct gcggcataaa attcgcgagc acatcctgat tcatggagat	840
ctgcggacca caactaccgt gaatgtggct ggggaggaaa tgcaggtgga aacaatggtg	900
gccgctgagg acgccgatga aacaactgtg	930

<210> 16

<211> 304

<212> PRT

<213> Heterochlamydomonas inaequalis

<400> 16

Met Gly Gly Ile Gly Gly Gly Gly Ile Gln Pro Arg Asp Tyr Ser Tyr
 1 5 10 15

Gly Ala Asn Gly Thr Val Cys Val Asn Pro Asp Val Cys Phe Cys Leu
 20 25 30

Asp Trp Gln Gln Pro Phe Gly Ser Asn Met Glu Asn Asn Val Ser Gln
 35 40 45

Gly Phe Gln Leu Phe Thr Ile Ala Leu Ser Ala Cys Ile Leu Met Phe
 50 55 60

Tyr Ala Tyr Glu Trp Tyr Lys Ala Thr Cys Gly Trp Glu Glu Ile Tyr
 65 70 75 80

Val Cys Val Val Glu Met Ser Lys Ile Cys Ile Glu Leu Val His Glu
 85 90 95

Tyr Asp Thr Pro Phe Cys Leu Tyr Leu Ala Thr Gly Ser Arg Val Leu
 100 105 110

Trp Leu Arg Tyr Ala Glu Trp Leu Met Thr Cys Pro Val Ile Leu Ile
 115 120 125

His Leu Ser Asn Ile Thr Gly Leu Gly Thr Asp Tyr Asn Lys Arg Thr
 130 135 140

Met Val Leu Leu Met Ser Asp Ile Gly Cys Ile Val Phe Gly Ala Thr
 145 150 155 160

Ala Ala Phe Ala Asn Glu Gly Tyr Val Lys Cys Ala Cys Phe Leu Leu
 165 170 175

Gly Met Ala Trp Gly Met Asn Thr Phe Tyr Asn Ala Ala Lys Val Tyr
 180 185 190

Tyr Glu Ser Tyr Val Leu Val Pro Ser Gly Ile Cys Lys Leu Leu Val
 195 200 205

Ala Val Met Ala Gly Leu Tyr Tyr Val Ser Trp Ser Leu Phe Pro Ile
 210 215 220

Leu Phe Ala Ile Gly Pro Glu Gly Phe Gly Val Ile Ser Leu Gln Ala
 225 230 235 240

Ser Thr Ile Gly His Thr Ile Ala Asp Val Leu Ser Lys Asn Met Trp
 245 250 255

Gly Leu Met Gly His Phe Leu Arg Val Gln Ile Tyr Lys His Ile Leu
 260 265 270

Leu His Gly Asn Ile Arg Lys Pro Ile Lys Leu His Met Leu Gly Glu
 275 280 285

Glu Val Glu Val Met Ala Leu Val Ser Glu Glu Gly Glu Asp Thr Val
 290 295 300

<210> 17

<211> 912

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide; Mammalian-condon optimized DNA

<400> 17

atgggaggaa ttggcggagg cggcattcag cctagagact acagctacgg cgccaacgga	60
acagtctgcg tgaaccccgga cgtctgcttc tgtctggatt ggcagcagcc cttcggctct	120
aacatggaga acaacgtgtc ccagggttc cagctgttta ccacgccct gagcgcctgc	180
atcctgatgt tctacgcta cgagtgttac aaggccactt gcggttggga ggagatctac	240
gtctgcgtgg tggagatgag caagatttgc atcgagctgg tgcacgagta cgacaccccc	300
ttttgcctgt acctggccac cggcagcaga gtcctctggc tgagatacgc cgagtggctc	360
atgacttgcc ccgtgatcct gatccacctg agcaacatca ccggactggg caccgactac	420
aacaagcggg ccatggtgct cctgatgagc gacatcggtt gcacgtgtt cggcgccaca	480
gcagcattcg ccaacgaggg ctacgtgaag tgcgcttgtt tcctgctggg catggcttgg	540
ggcatgaaca ctttctacaa cgccgccaag gtgtactacg agagctacgt gctggtgccc	600
tccggaattt gcaagctgct ggtggccgtg atggccggac tgtactacgt gtcttgagc	660
ctgttcccca tcctgtttgc catcgcccca gagggatttg gcgtgatcag cctgcaggcc	720
agcaccattg gccacacaat cgccgacgtg ctgagcaaga acatgtgggg cctgatgggc	780
cacttcctgc gggtcgagat ctacaagcac atcctgctgc acggcaacat ccggaagcct	840
atcaagctgc acatgctggg cgaggaggtg gaagtgatgg ctctggtgtc cgaggaggga	900
gaggataccg tg	912

<210> 18

<211> 927

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide; Mammalian-condon optimized DNA

<400> 18

atggactatg gcggcgcttt gtctgccgtc ggacgcgaac ttttgttcgt tactaatcct	60
gtggtggtga acgggtccgt cctggtccct gaggatcaat gttactgtgc cggatggatt	120
gaatctcgcg gcacgaacgg cgctcagacc gcgtcaaatg tcctgcagtg gcttgacgca	180
ggattcagca ttttgctgct gatgttctat gcctacaaa cctggaaatc tacatgcggc	240
tgggaggaga tctatgtgtg cgccattgaa atggttaagg tgattctcga gttctttttt	300
gagtttaaga atccctctat gctctacctt gccacaggac accgggtgca gtggctgcgc	360
tatgcagagt ggctgctcac ttgtcctgtc atccttatcc acctgagcaa cctcaccggc	420
ctgagcaacg actacagcag gagaacctat ggactccttg tctcagacat cgggactatc	480
gtgtgggggg ctaccagcgc catggcaacc ggctatgtta aagtcactct cttttgtctt	540

```

ggattgtgct atggcgcgaa cacatttttt cagcccgcca aagcatatat cgagggttat      600
catactgtgc caaagggtcg gtgccgccag gtcgtgaccg gcatggcatg gctgtttttc      660
gtgagctggg gtatgttccc aattctcttc attttggggc ccgaagggtt tggcgtcctg      720
agcgtctatg gctccaccgt aggtcacacg attattgatc tgatgagtaa aaattgttgg      780
gggttggttg gacactacct gcgcgtcctg atccacgagc acatattgat tcacggagat      840
atccgcaaaa ccaccaaact gaacatcggc ggaacggaga tcgaggtcga gactctcgtc      900
gaagacgaag ccgaggccgg agccgtg                                           927

```

<210> 19

<211> 309

<212> PRT

<213> Chlamydomonas reinhardtii

<400> 19

```

Met Asp Tyr Gly Gly Ala Leu Ser Ala Val Gly Arg Glu Leu Leu Phe
1           5           10          15

Val Thr Asn Pro Val Val Val Asn Gly Ser Val Leu Val Pro Glu Asp
          20          25          30

Gln Cys Tyr Cys Ala Gly Trp Ile Glu Ser Arg Gly Thr Asn Gly Ala
          35          40          45

Gln Thr Ala Ser Asn Val Leu Gln Trp Leu Ala Ala Gly Phe Ser Ile
          50          55          60

Leu Leu Leu Met Phe Tyr Ala Tyr Gln Thr Trp Lys Ser Thr Cys Gly
65          70          75          80

Trp Glu Glu Ile Tyr Val Cys Ala Ile Glu Met Val Lys Val Ile Leu
          85          90          95

Glu Phe Phe Phe Glu Phe Lys Asn Pro Ser Met Leu Tyr Leu Ala Thr
          100         105         110

Gly His Arg Val Gln Trp Leu Arg Tyr Ala Glu Trp Leu Leu Thr Cys
          115         120         125

Pro Val Ile Leu Ile His Leu Ser Asn Leu Thr Gly Leu Ser Asn Asp
          130         135         140

Tyr Ser Arg Arg Thr Met Gly Leu Leu Val Ser Asp Ile Gly Thr Ile
145          150         155         160

Val Trp Gly Ala Thr Ser Ala Met Ala Thr Gly Tyr Val Lys Val Ile
          165         170         175

Phe Phe Cys Leu Gly Leu Cys Tyr Gly Ala Asn Thr Phe Phe His Ala
          180         185         190

Ala Lys Ala Tyr Ile Glu Gly Tyr His Thr Val Pro Lys Gly Arg Cys
          195         200         205

```

Arg Gln Val Val Thr Gly Met Ala Trp Leu Phe Phe Val Ser Trp Gly
 210 215 220

Met Phe Pro Ile Leu Phe Ile Leu Gly Pro Glu Gly Phe Gly Val Leu
 225 230 235 240

Ser Val Tyr Gly Ser Thr Val Gly His Thr Ile Ile Asp Leu Met Ser
 245 250 255

Lys Asn Cys Trp Gly Leu Leu Gly His Tyr Leu Arg Val Leu Ile His
 260 265 270

Glu His Ile Leu Ile His Gly Asp Ile Arg Lys Thr Thr Lys Leu Asn
 275 280 285

Ile Gly Gly Thr Glu Ile Glu Val Glu Thr Leu Val Glu Asp Glu Ala
 290 295 300

Glu Ala Gly Ala Val
 305

<210> 20

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 20

gtcccgtagc cgctgctcct gctgttggca gccgccctgg ctccgactca gacgcggggc 60

<210> 21

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 21

Met Val Pro Cys Thr Leu Leu Leu Leu Leu Ala Ala Ala Leu Ala Pro
 1 5 10 15

Thr Gln Thr Arg Ala
 20

<210> 22

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 22

ttctgctacg agaatgaagt g 21

<210> 23

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 23

Phe Cys Tyr Glu Asn Glu Val
1 5

<210> 24

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

<400> 24

aaatccagaa ttacttctga aggggagtat atccctctgg atcaaataga catcaatggt 60

<210> 25

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 25

Lys Ser Arg Ile Thr Ser Glu Gly Glu Tyr Ile Pro Leu Asp Gln Ile
1 5 10 15

Asp Ile Asn Val
20

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US20110165681A](#) [\[0079\]](#) [\[0114\]](#)
- [US20100234273A](#) [\[0114\]](#)
- [US2012064665W](#) [\[0154\]](#)
- [US61559076B](#) [\[0154\]](#)

Non-patent literature cited in the description

- HAN, X.E. S. BOYDENPLoS ONE, 2007, vol. 2, e299- [\[0004\]](#)
- HAN, X.E. S. BOYDENPLoS ONE, 2007, vol. 2, 3e299- [\[0004\]](#)
- BOYDEN, E. S.Nat Neurosci., 2005, vol. 8, 91263-8 [\[0004\]](#)
- LIN, J. et al.Biophys. J., 2009, vol. 96, 51803-14 [\[0031\]](#)
- WANG, H. et al.2007 Proc Natl Acad Sci U S A., 2007, vol. 104, 198143-8 [\[0031\]](#)
- Remington's Pharmaceutical Sciences19900000 [\[0104\]](#)
- CHOW BYMethods Enzymol., 2011, vol. 497, 425-43 [\[0114\]](#)
- CHOW, BY et al.Nature, 2010, vol. 463, 727798-102 [\[0114\]](#)

PATENTKRAV

1. Isoleret lysaktiveret ionkanalpolypeptid omfattende en aminosyresekvens af et vildtype eller modificeret lysaktiveret *Stigeoclonium helveticum*-kanalpolypeptid,

5

hvor aminosyresekvensen af det lysaktiverede ionkanalpolypeptid omfatter SEQ ID NO: 7, eller aminosyresekvensen af det lysaktiverede ionkanalpolypeptid omfatter en modificeret *Stigeoclonium helveticum* lysaktiveret ionkanalsekvens, der har mindst 70% identitet med aminosyrerne 61-295 af SEQ ID NO: 7 og 95%

10

identitet med de resterende aminosyrer i sekvensen angivet som SEQ ID NO: 7;

hvorved en nukleinsyre- eller polypeptidsekvens kan udtrykkes naturligt i en celle eller organisme af et medlem af *Stigeoclonium*-slægten, men forudsat at sekvensen ikke er en del af eller er inkluderet i en *Stigeoclonium*-celle eller -organisme, som den anses for at være isoleret fra.

15

2. Fremgangsmåde til ændring af en membrans ionledningsevne, hvilken fremgangsmåde omfatter:

20

a) ekspresion i en værtsmembran et lysaktiveret ionkanalpolypeptid som defineret i krav 1, og

b) kontakt mellem det lysaktiverede ionkanalpolypeptid og et lys, der aktiverer den lysaktiverede ionkanal og ændrer membranens ionledningsevnen,

hvor fremgangsmåden udføres *in vitro*.

25

3. Isoleret lysaktiveret ionkanalpolypeptid ifølge krav 1 eller fremgangsmåde ifølge krav 2, hvor aminosyresekvensen af det lysaktiverede ionkanalpolypeptid omfatter en modificeret *Stigeoclonium helveticum* lysaktiveret ionkanalsekvens med mindst 75% eller 80% eller 85% eller 90% eller 95% eller 99% identitet med aminosyrerne 61-295 i SEQ ID NO: 7 og 95% eller 96% eller 97% eller 98% eller 99% eller 100% identitet med de resterende aminosyrer i sekvensen angivet som SEQ ID NO: 7.

30

4. Isoleret lysaktiveret ionkanalpolypeptid ifølge krav 1, hvor det lysaktiverede ionkanalpolypeptid udtrykkes i en membran, og hvor membranen er:

(a) en membran af en pattedyrscelle, eventuelt en exciterbar celle; eller

(b) en cellemembran af en neuronal celle, en nervesystemcelle, en hjertecelle, en kredsløbssystemcelle, en visuel systemcelle eller en auditiv systemcelle.

5 5. Nukleinsyre, der koder for det isolerede lysaktiverede ionkanalpolypeptid som defineret i et hvilket som helst af kravene 1, 3 eller 4.

6. Nukleinsyre ifølge krav 5, hvor den nukleinsyresekvens, der koder for det lysaktiverede ionkanalpolypeptid, omfatter nukleinsyresekvensen angivet som SEQ ID NO: 8.

10 7. Vektor omfattende nukleinsyren ifølge krav 5 eller 6.

8. Vektor ifølge krav 7, hvor vektoren er en ekspressionsvektor.

15 9. Fremgangsmåde til vurdering af virkningen af en kandidatforbindelse på en membrans ionledningsevne, hvilken fremgangsmåde omfatter:

a) kontakt mellem en testmembran, der omfatter det isolerede lysaktiverede ionkanalpolypeptid ifølge et hvilket som helst af kravene 1, 3 eller 4, og lys under betingelser, der er egnede til at ændre membranens ionledningsevne;

b) kontakt mellem testmembranen og en kandidatforbindelse; og

20 c) identificering af tilstedeværelsen eller fraværet af en ændring i ionledningsevne hos den membran, der er bragt i kontakt med lyset og kandidatforbindelsen, sammenlignet med ionledningsevnen i en kontrolcelle, der er bragt i kontakt med lyset, og som ikke er bragt i kontakt med kandidatforbindelsen;

25 hvor en ændring i ionledningsevnen i testmembranen sammenlignet med kontrollen indikerer en virkning af kandidatforbindelsen på testmembranens ionledningsevne.

30 10. Lysaktiveret ionkanalpolypeptid ifølge et hvilket som helst af kravene 1, 3 eller 4, nukleinsyre ifølge et hvilket som helst af kravene 5-6 eller vektor ifølge et hvilket som helst af kravene 7-8 til anvendelse i en fremgangsmåde til behandling af en lidelse i et individ, hvilken fremgangsmåde omfatter:

- a) administration til et individ, der har behov for en sådan behandling, af en terapeutisk effektiv mængde af det lysaktiverede ionkanalpolypeptid, nukleinsyren eller vektoren til behandling af lidelsen, hvorved administrationen resulterer i ekspresion af den lysaktiverede ionkanal i en celle i individet, og
- 5 b) kontakt af cellen med lys og aktivering af den lysaktiverede ionkanal i cellen under betingelser, der er tilstrækkelige til at ændre en cellemembrans ionledningsevne, hvor ændring af cellemembranens ledningsevne behandler lidelsen.
- 10 11. Lysaktiveret ionkanalpolypeptid som defineret i krav 1, 3 eller 4 til anvendelse i en fremgangsmåde til medicinsk behandling af et individ.
12. Polypeptid til anvendelse i en fremgangsmåde til medicinsk behandling ifølge krav 11, hvor lidelsen er valgt blandt alkalose og lidelser i det visuelle system.
- 15 13. Fremgangsmåde ifølge krav 9 eller polypeptid, nukleinsyre eller vektore til anvendelse i en fremgangsmåde til behandling af en lidelse ifølge krav 10, hvor ændring af membranens ionledningsevnen depolariserer cellen.
- 20 14. Polypeptid, nukleinsyre eller vektor til anvendelse i en fremgangsmåde til behandling af en lidelse ifølge krav 10, hvor lidelsen er valgt blandt skader, hjerneskade og degenerative neurologiske tilstande.
- 25 15. Polypeptid, nukleinsyre eller vektor til anvendelse i en fremgangsmåde til behandling af en lidelse ifølge krav 14, hvor lidelsen er valgt blandt Parkinsons sygdom, Alzheimers sygdom, anfald, synstab og høretab.

DRAWINGS




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A


0.1 mW mm⁻²
5 ms 5 Hz



0.2 mW mm⁻²
5 ms 5 Hz



0.1 mW mm⁻²
1000 ms pulse



1s

FIG. 5B




FIG. 6A




FIG. 6C




FIG. 6B




FIG. 6D




FIG. 7A




FIG. 7B




FIG.8A




FIG.8B





FIG.8C






FIG. 10




FIG. 11A



FIG. 11B




FIG. 11C




FIG. 12




FIG. 13A

FIG. 13B

FIG. 13C




FIG. 14